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Summary
The aim of this study was to build a mathematical model that describes the
binding of 17-β-estradiol (E2) to estrogen receptor α (ER-α) and the influ-
ence the sex hormone binding globulin (SHBG) has on this interaction. The
influence of SHBG on the transactivation of an estrogen response element,
via ligand bound ER-α, was also studied.
COS-1 cells, derived from the kidney of a green african monkey, were used
to study the binding of E2 to ER-α in the absence of SHBG. The influ-
ence of SHBG on the binding of E2 to ER-α was studied using Hep89 cells,
human hepatacoma carcinoma, which express SHBG endogenously and are
stably transfected with the ER-α gene. Human pregnancy plasma was used
to study the interaction of E2 with SHBG in the absence of ER-α.
The results of this study have shown that the Kd (E2) for ER-α was deter-
mined as between 3.4nM and 4.4nM in the absence of SHBG. With respect
to the binding of E2 to ER-α it was not possible to determine the Kd app and
Bmax for ER-α using the Hep89 experimental system. The Kd (E2) for SHBG
was not determined using the human pregnancy plasma experimental system.
With the aid of mathematical modelling, a model of the Hep89 and human
pregnancy plasma experimental systems, was built. The results of the nu-
merical modelling, using mathematical modelling, showed that the presence
of albumin together with SHBG was the reason that the Kd app (E2) could
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not be determined in the Hep89 experimental system. With respect to the
use of human pregnancy plasma to determine the Kd (E2) for SHBG it was
shown that if the plasma was diluted 200 times it would have been possible
to determine the Kd app (E2) for SHBG, in the presence of albumin.
Ligand independent transactivation of an estrogen response element was
shown to be a problem in the COS-1 cell system when promoter reporter
gene assays were undertaken. As COS-1 cells were used as a control for the
absence of SHBG no further promoter reporter gene assays were undertaken
using the Hep89 experimental system.
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Samevatting
Die doel van hierdie studie was die bou van ‘n wiskundige model wat die
verbinding van E2 met die estrogeenreseptor α (ER-α) en die invloed wat
die geslagshormoon-verbindingglobulien (SHBG) op hierdie interaksie het,
beskryf. Die effek van SHBG op die transaktivering van ‘n estrogeen respon-
selement, via die ligandverbonde ER-α, is ook bestudeer.
COS-1-selle uit die nier van ‘n groen afrika-aap is gebruik om die verbinding
van E2 met ER-α in die afwesigheid van SHBG te bestudeer. Die invloed van
SHBG op die verbinding van E2 met ER-α, is bestudeer deur gebruik te maak
van Hep89-selle, die menslike lewergeswelkarsinoom, wat SHBG uitwendig
afgee en wat stabiel getransfesteer kan word met die ER-α geen. Menslike
swangerskapplasma is gebruik om die interaksie van E2 met SHBG in die
afwesigheid van ER-α te bestudeer.
Die uitslag van hierdie studie toon aan dat die Kd (E2) vir ER-α vasgestel
tussen 3.4nM en 4.4nM in die afwesigheid van SHBG. Met betrekking tot die
verbinding van E2 met ER-α, was dit nie moontlik om die Kd (E2) en Bmax app
vir ER-α met die gebruik van die Hep89 eksperimentele stelsel vas te stel
nie. Die Kd (E2) vir SHBG is nie vasgestel deur die gebruik van die menslike
swangerskapplasma eksperimentele stelsel nie.
‘n Model van die Hep89 en menslike swangerskapplasma eksperimentele stelsels
is met behulp van wiskundige modellering gebou. Die uitslag van die nu-
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meriese modellering, met gebruik van wiskundige modellering, toon dat die
teenwoordigheid van albumien, saammet SHBG, die rede was dat die Kd app (E2)
nie in die Hep89 eksperimentele stelsel vasgestel kon word nie. Wat betref
die gebruik van menslike swangerskapplasma om die Kd (E2) vir SHBG vas
te stel, is daar aangetoon dat, indien die plasma 200 maal verdun was, dit
moontlik sou gewees het om die Kd app (E2) vir SHBG in die teenwoordigheid
van albumien vas te stel.
Promotor verkilkkergeen toetse het ligandonafhanklike transaktiveering van
‘n estrogeen responselement aangetoon as ‘n probleem in die COS-1-selle
stelsel. Omdat COS-1-selle gebruik is as ‘n kontrole vir die afwesigheid van
SHBG, is geen verdere promotor verkilkkergeen toetse onderneem met die
gebruik van die Hep89 eksperimentele stelsel nie.
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Chapter 1
Introduction
The steroid hormone 17-β-estradiol (E2), regulates endocrine functions by
binding the two estrogen receptor isoforms namely ER-α and ER-β. E2 is
found in the plasma in two distinct forms, bound and unbound. In humans
the sex hormone binding globulin (SHBG) binds E2 and subsequently regu-
lates the amount of unbound E2 [1]. It has been suggested that the unbound
form of E2 is the bio-active form. However, it has also been found that un-
der certain circumstances that protein bound E2 is also available for tissue
uptake, this form of E2 thus also being a bio-active form of E2.
Most studies that focus on the effect of estrogenic compounds on the hu-
man endocrine system use E2 as a base reference. E2 is used as a prototypical
endocrine-active compound (EAC). Endocrine active compounds are a group
of chemicals that have been shown to influence the endocrine system, some
of which specifically bind to the estrogen receptor.
The primary aim of this study is to determine the effect that SHBG has
on the binding of E2 to the human ER-α. The effect that SHBG has on the
transactivation of an estrogenically sensitive gene was to also be described.
The data that is collected will then be used to build a mathematical model
which describes the effect that SHBG had on the binding of E2 to the ER-α.
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To achieve the proposed aims of this study an experimental system is re-
quired in which the interaction of E2 with ER-α can be investigated in the
presence or absence of SHBG. The proposed experimental system consists
of two cell lines and human pregnancy plasma. The cell lines being used
either lacked SHBG (COS-1 cells) or endogenously expressed SHBG (Hep89
cells). COS-1 cells were derived from the kidney of the green african monkey
and don’t contain any endogenous SHBG. Hep89 cells were created by sta-
bly transfecting HepG2 cells with pCDNA3-ER-α to create a cell line that
expresses ER-α. HepG2 cells were derived from a human liver carcinoma
and are known to produce SHBG endogenously. Human pregnancy plasma
was being used because it contains SHBG endogenously, however, does not
contain ER-α.
To build the operational model of agonism a number of parameters, de-
scribed in Table 4.1, are required. The kinetic binding constants (Kd and
Bmax (ER-α)) are determined through the use of either competitive or satu-
ration binding assays, while the effect of E2 on an ERE will be determined
using promoter reporter gene studies. The Kd (E2) and Bmax for ER-α will
be determined using the COS-1 experimental system. The Kd app (E2) and
Bmax app (ER-α) will be determined using the Hep89 experimental system. Hu-
man pregnancy plasma is used to determine the Kd (E2) in the absence of
ER-α. The cell volumes for both the Hep89 and COS-1 experimental system
will also be determined for use in the model. The metabolism of E2 in the
COS-1 and Hep89 experimental systems will also be studied to determine if
it is necessary to include this variable in the model. In this thesis a review
of the literature concerning ER-α is presented in Chapter 2. As mentioned
earlier it is known that SHBG binds E2 and thus a review of SHBG action
has been included in Chapter 3. The various models that currently exist to
describe the effect of ligands on responsive genes are discussed in Chapter 5.
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Chapter 4 describes the development of an experimental system to inves-
tigate the effect of E2 in the presence/absence of SHBG. These experimental
systems were used to obtain binding data concerning the Kd of ER-α as well
as transactivation studies. The binding data for SHBG, obtained using the
human pregnancy plasma experimental system, will also be presented.
The design of a mathematical model to describe the effect that SHBG and
albumin has on the binding of E2 to the human ER-α, is given in Chapter 6.
The conclusions of this study are presented in Chapter 7.
Table 1.1: Parameters needed to build the mathematical model of
agonism
Binding proteins Binding constants
hER-α Kd (E2) (intracellular)
Bmax (ER-α) (intracellular)
hSHBG Kd (E2)
Bmax (SHBG) (intracellular and extracellular)
Volume of compartments Experimental system
Cytoplasm COS-1 and Hep89 cells
Medium COS-1 and Hep89 cells
Metabolic studies Experimental system
Metabolism of E2 COS-1
Metabolism of E2 Hep89
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Chapter 2
Estrogen receptor
2.1 Introduction
The estrogen receptor is a ligand activated transcription factor and is part of
the nuclear receptor super-family [2], Table 2.1. The members of the nuclear
receptor super-family all share common structural features as will be dis-
cussed in section 2.2. A number of estrogenic compounds have an influence
on the human endocrine system via the estrogen receptor α. These com-
pounds include natural and synthetic estrogenic compounds such as phytoe-
strogens, endocrine disruptors and selective endocrine receptor modulators
(SERMS).
Phytoestrogens are non-steroidal estrogenic compounds that are produced
by plants. SERMS function as agonists or antagonists depending on the tis-
sue in which they are located [3]. The prevalence and modulating activity of
these compounds has spurred research into the effects, in the human body,
and removal of certain compounds from the environment.
E2, via the ER-α regulates the reproductive system in mammals and has an
effect in a number of tissues: liver, bone, brain and cardiovascular system [4].
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2.1 Introduction
This review will concentrate on the mechanisms through which the human
ER-α modulates the human endocrine system.
Table 2.1: Superfamily of nuclear receptors
Class Description
Class I The nuclear receptors which belong to this family are the es-
trogen (ER), glucocorticoid (GR), mineralocorticoid (MR),
progestin (PR) and finally the androgen receptor (AR) and
have long A/B domains. They have been placed in this
group because when no ligand is bound they are found as-
sociated with chaperones such as heat shock proteins, im-
munophilins and others [5, 6]. Once ligand binds the heat-
shock proteins disassociate, the receptor dimerizes and binds
to hormone response elements in the promoter region of tar-
get genes and modulate their transcription [7].
Class II This class of receptors has short A/B domains and is com-
posed of the thyroid (TR), dihydroxyvitamin D3 (VDR),
trans retinoic acid (RAR), 9-cis retinoic acid (RXR) and
most of the orphan nuclear receptors. These receptors do
not associate with heat shock proteins and bind to DNA el-
ements consisting of half sites as homodimers and sometimes
monomers.
Class III These receptors, for example SF-1, function as monomers
and are associated with constitutive transcription.
Class IV These receptors have characteristics of both Class I and II
receptors.
5
2.2 Structural and functional domains
2.2 Structural and functional domains
ER-α has six functional domains as represented in Table 2.2 and Figure
2.1. These domains are involved in a number of functions which include lig-
and binding, dimerization, DNA binding and transcriptional activation [8].
Table 2.2: Structural domains of nuclear receptors [8]
Domain Function
A/B Contains the activation function 1
C Involved in DNA binding (DBD)
D Involved in the conformational changes of the
ligand bound receptor (hinge region)
E Involved in ligand binding, contains AF-2 do-
main (LBD)
F Conformation of protein-protein interactions
involved in transcription
Figure 2.1: Domain structure of the human ER-α [9].
A/B domain This is also called the N-terminal domain and contains activa-
tion function-1 (AF-1). The AF-1 domain is involved in ligand-independent
transactivation and interacts with the core transcription machinery [10].
C domain Also called the DNA binding domain (DBD), it is a hydrophilic
region which contains sequences involved in binding of ER-α to DNA. The
domain contains two zinc type II binding motifs, in which each zinc ion is
6
2.2 Structural and functional domains
tetrahedrally liganded by four conserved cysteine residues [11]. The discrim-
ination between promoter sequences is controlled by the P-box. For ER-α
the P-box is defined as the first three amino acids (CEGCKA) [12] found at
the base of the first zinc binding motif [13]. As such the P-box is involved in
the specificity and selectivity of the binding of the ligand bound ER-α to the
ERE. Another box, termed the D-box, is located in the second zinc binding
motif. The D-box, spanning cysteine residues 5-6, is used to differentiate
between ERE’s that have similar sequences, of which, the half site spacing
is different [14]. Other functions that are related to the DBD include weak
dimerization properties in the absence of ligand. The DBD also contains
ligand independent nuclear translocation signals which are used in the trans-
port of the unliganded ER-α to the nucleus [15, 16].
D domain This domain is also known as the hinge region and its functions
are to provide flexibility to the receptor protein when altering conformation
upon ligand binding [17].
E domain Also referred to as the ligand binding domain (LBD) and as
such is involved in the binding of ligand to the ER [18]. Regions found in
this domain are involved in:
Dimerization of monomers
Interaction with heat shock proteins (Hsp)
Interaction with transcriptional co-regulators
Ligand dependent activation and nuclear translocation
The LBD is made up of 12 α helices and two β sheets as well as secondary
structures that are arranged in a α helical “sandwich” [7]. The AF-2 function
contains a highly conserved amphiphatic α helix, called helix 12 (H12) also
called the AF-2 AD core. This α helix has been found to be essential in the
ligand inducible AF-2 function [18]. Amino acids in the region 521-528 of
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the ER-α are involved in the recognition and binding of ligands [19]. The
binding of stereochemically different compounds alters the tertiary confor-
mation that the ER-α adopts. This alteration of conformation affects the
co-regulators that can bind the ER-α [18].
The role that the LBD plays with respect to dimerization is controlled by a
leucine zipper type mechanism [20] which is involved in the conversion of 4S
to 5S ER [21]. This function is only active in the presence of ligand as in the
absence of ligand the DBD controls dimerization.
F domain This region possibly plays a role in the conformation of protein-
protein interactions necessary for effectiveness of transcription [22].
2.3 Subtypes
A number of ER isoforms exist, however, only the ER-α and ER-β isoforms
will be discussed with the emphasis on the ER-α isoform. ER-α which was
first isolated and cloned from MCF-7 cells in the late 1980’s. ER-α, classified
as the primary isoform, is a 66kDa which is found in it’s unliganded form in
the nucleus [23, 24, 25]. A 46kDa isoform of ER-α, has been isolated and
characterized [26]. This isoform lacks the first 173 amino acids of the wild
type ER-α and negatively regulates ER-α [26]. A number of splice variants
of ER-α are known, however, it is not known whether they are expressed as
functional proteins [27].
ER-β, an isoform of ER, was first isolated and cloned from rat prostrate
in 1996 [28]. Since then the mouse [29] and human ER-β [30, 31] isoforms
have also been cloned. The full length ER-β protein is expressed as a 59.2
kDa protein and shows homology with ER-α. The A/B domain of ER-β is
30% homologous to the same domain in the ER-α. The DNA binding do-
main (C domain) shares 96% homology with that of ER-α whilst the D and
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E/F domains share 30% and 53% homology, respectively, with the same do-
mains found in ER-α [32]. Even though there are differences in the domains
it has been found that ER-α and β have a similar affinity for E2, however,
there are differences in affinity for other ligands such as phytoestrogens and
antiestrogens [33]. In addition ER-α and ER-β are located in different tissues
and ER-β is considered to exert a dominant negative effect on ER-α signaling.
ER-α is located in the nucleus when no ligand is bound, however it has also
been found that ER-α can be found in the plasma membrane [34]. In the
membrane ER-α appears to be localize mainly in discrete domains, known
as caveole. The exact mechanism of how this small pool of ER translocates
to the membrane is currently unknown [35].
Estrogen related receptors (ERR) are orphan nuclear receptors and form
part of a sub-family that share amino acid homology with the ER [36]. Both
ERR-α and β were first isolated in 1988 [37]. A third ERR, the estrogen
related receptor gamma (ERR-γ), was isolated in 1999 [38]. When compar-
ing the DBD ERR’s have a 60% homology to ER-α and when comparing the
LBD’s the homology is found to be less than 35%.
2.4 Distribution and physiological role
The highest concentration of estrogen receptors are located in tissues with
reproductive functions. These tissues include the mammary glands; ovaries;
vagina; uterus, however, estrogen receptors can also be found in a number of
other tissues, Table 2.3. Many physiological conditions, such as arterioscle-
rosis, osteoporosis and degenerative processes of the central nervous system
are linked to the presence of estrogenic compounds. The following discussion
will center on the distribution of and the role that estrogen receptors play in
various tissues.
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Table 2.3: Tissue distribution of ER-α [4]
Ovary Kidney
Vagina Islets of Langerhaan
Uterus Liver
Mammary gland Bone
Adrenal gland Cardiovascular system
Prostrate Macrophages
Pituitary gland Thymocytes
Hypothalamus Lymphoid cells
Leydig cells Endothelial cells
Osteoblastic cells
Glia cells
Schwann cells
Colon
The importance of estrogen in the development of female breast tissue has
been known for a long time and is well documented. Using ER-α knockout
mice (ERKO) it has been shown that the development of the mammary gland
tissue is impeded [39]. This is because of the lack of ER-α. In addition, it
has been shown that over 70% of breast cancers are sensitive to the presence
of estrogens acting via the ER-α.
In the urogenital tract it has been found that both ER-α and β are expressed
in a number of tissues including the ovaries, uterus, testes and prostrate. In
these tissues the ER isoforms are involved in the regulation of sexual devel-
opment as well as fertility [4].
Osteoporosis has been linked to a deficiency of estrogen, normally after
menopause. Estrogens are known to be involved in the maintenance of bone
resorption and bone formation [40]. It has been proposed that ER-α regu-
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lates the effects of estrogens on bone tissue because ER-α is localized in both
the bone forming osteoblasts [41] and bone resorbing osteoclasts [42].
With respect to the role that estrogens play in the cardiovascular system
it has been shown that women are less likely to develop cardiovascular dis-
ease at an early age [43]. Both ER-α and ER-β have been linked to a number
of effects seen in vascular endothelial cells [44], smooth muscle cells [45], and
myocardial cells [46]. These effects include: non-genomic vasodilation [47]
and nitric-oxide synthesis [48]. Estrogens have also been found to have an
indirect influence on the cardiovascular system, via ER-α [49]. The indirect
action of estrogens on the cardiovascular system can be linked to the effects
of estrogen in the liver, where it is known that estrogens regulate the serum
levels of lipids and cholesterol [43].
Estrogens are reported to have a number of functions in the central nervous
system (CNS) such as learning, memory, awareness, fine motor skills, tem-
perature regulation, mood and reproductive function. The hypothalamic-
pituitary axis (HPG) regulates overall endocrine homeostasis in the body.
Estrogen, through effects on the HPG-axis, modulates expression and secre-
tion of several hormones from the anterior pituitary gland such as leutinizing
hormone (LH), follicle stimulating hormone (FSH), growth hormone (GH)
and prolactin (PRL). Both ER-α and ER-β are expressed in the pituitary,
however, ER-α predominates in the gonadotrophs and lactotrophs. Both iso-
forms of the ER are also expressed in the pre-optic area of the hypothalamus
and are believed to be involved in the regulation of expression of the pituitary
hormones. The serum levels of LH and FSH are directly controlled by the
hypothalamic gonadotropin releasing hormone (GnRH). The most important
physiological determinants of the serum gonadotropin levels are circulating
estrogen, other sex steroids and glycoproteins. There is a strong inverse cor-
relation between the circulating levels of inhibin, a protein which inhibits the
action of FSH synthesis and secretion, in females and FSH. The main source
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of inhibin (inhibin A and B) production in females is in the ovary. Inhibin
B is expressed in the early follicular phase with a peak at the mid-follicular
phase whilst inhibin A is expressed by the dominant follicle and the corpeus
luteum with a peak in the late follicular and in the mid leutal phase. The
endocrine system is controlled, in part, by both negative and positive feed-
back, Figure 2.2. It has been found that estrogen has a negative feedback on
the release of FSH from the pituitary, which in turn controls ovarian estrogen
production [50].
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Figure 2.2: Feedback processes which control the concentration of
estradiol [50](+) positive feedback, (-) negative feedback
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2.5 Molecular mechanism of estrogen action
The ER’s are transcriptional factors that bind to the regulatory regions
of genes, specifically estrogen response elements (ERE). When the ER-α
is bound by agonists it undergoes a conformational change. This confor-
mational change induces the disassociation of intra-cytoplasmic chaperones
such as heat shock proteins Hsp 70 and 90 [51]. This having been done the
ligand bound receptor is now free to bind to DNA after which the transcrip-
tional process is controlled by the recruitment of various cofactors and local
transcription machinery.
2.5.1 Ligand-dependent genomic actions
One of the mechanisms through which estrogenic compounds have an effect
in the human body is through the interaction of ligand bound ER-α with an
estrogen response element (ERE). The ERE is a region of DNA where the
ER-α is known to interact directly with DNA. There are a number of known
ERE’s, however, the most responsive ERE is the vitellogenin ERE. This ERE
was isolated from the African clawed frog Xenopus laevis and has been found
to contain the consensus palindromic ERE sequence [52]. In mammals most
estrogenically sensitive genes contain non consensus ERE sequences [53].
It has been found that three specific amino acids within the proximal P-box
of the first zinc finger in the ER-α are used to bind to the ERE in a sequence
specific manner [49]. The second zinc finger is involved in receptor molecule
dimerization as well as ERE half-site spacing recognition. It has been found
that the structure of the ERE has an influence on the cofactors that are
recruited to the ER-ERE complex. It has, however, also been noted that
the type of ligand also plays a role in the afore mentioned function. When
E2 is bound to ER-α the ERE is the major determinant of which cofactors
are recruited to the ER-ligand-ERE complex. However, when antiestrogens
are bound the ERE loses it’s influence over which AF-2 dependent cofactors
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are recruited [11]. There are two main ways in which ER-α can interact
with ERE’s. The first mechanism is the classical mechanism through which
ER-α associates directly with the promoter sequence of the ERE. Another
mechanism through which the ER-α can interact with the ERE is known as
tethering. The tethering mechanism is defined, in the case of ER-α, as the
interaction of the ER-α with the ERE via an intermediary protein. An ex-
ample of this mechanism is the indirect interaction, via c-fos/c-jun, between
ER-α and AP-1, Figure 2.3. It has been found that ER-α can interact in a
hormone dependent manner with the Sp1 transcription factor [54].
Both ER-α and ER-β can interact with the fos/jun transcription factor com-
plex on AP1 sites which results in the stimulation of gene expression in the
absence of E2 [55].
Interaction of ER-α with basal transcription factors
The initiation of transcription is controlled by RNA polymerase II, how-
ever, a number of basal transcription factors, TFIIA; TFIIB; TFIID; TFIIE;
TFIIE; TFIIF and TFIIH, must first assemble at the core promoter. The
transcription factor TFIID consists of the TATA binding protein and at least
eight tightly associated factors [57]. ER-α is known to interact directly with
TFIIB, TATA binding protein (TBP), and various transcription activation
factors (TAF’s) of TFIID directly [52]. ER-α interacts with the TBP using
both AF-1 and AF-2 domains as interaction surfaces [58]. The interaction
of ER-α with hTAFII30 is controlled by the ligand binding domain of ER-α.
Although this interaction is ligand independent it is required for the ligand
dependent ER-α mediated activation of transcription [59]
Interaction with co-activators
ER-α interacts with a number of proteins, some of which have been shown to
have an influence on transcription. These proteins that interact with ER-α
have been termed co-activators and have been shown to interact with other
15
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Figure 2.3: Models which suggest how ER-α controls gene expression
[56].
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steroid receptors. By definition co-activators are proteins that interact di-
rectly with steroid receptor and enhance transcription [60]. The following
discussion will concentrate on the interaction of ER-α with the p160 family,
RIP-140, TIF-α, CBP/p300 and p68 co-activators.
The p160 family of co-activators are separated into three separate groups
namely steroid receptor co-activator 1 (SRC-1), steroid receptor co-activator
2 (SRC-2) and steroid receptor co-activator 3 (SRC-2).
ERAP-140 and ERAP-160 were the first proteins shown to interact directly
with ER-α. Using an MCF-7 cell experimental system and GST pull-down
assays it was shown that ERAP-160 interacts with the ligand binding do-
main of ER-α, when ER-α is bound by E2 [61]. ERAP-160 has since been
cloned and is now named SRC-1 [62]. The functions of SRC-1 include the
stimulation of E2 mediated gene transcription and enhancing the interaction
between the N and C terminal domains of ER-α. It has been suggested that
SRC-1 integrates the AF-1 and AF-2 functions and allows full ER-α activa-
tion after ligand binding [63]. SRC-1 has histone acetyltransferase activity,
which is specific to histone H3 and H4. Using this activity SRC-1 is able
to acetylate lysine residues on the N-terminal tails of histones H3 and H4 in
chromatin. The acetylation of lysine residues in histones H3 and H4 results
in the alteration of nucleosomal formation and stability of the chromatin and
enhances the formation of a stable pre-initiation complex. The end result of
this process is to facilitate transcriptional activation by RNA polymerase II
[64, 65, 66]. SRC-1 can bind both Fos and Jun [67] as well as basal tran-
scription factors TBP and TFIIB [68], because of this it has been suggested
that SRC-1 may act as a bridge between the ERE and ligand activated ER-
α-Ap-1 complex and the DNA polymerase II initiation complex [69].
GRIP1, NCoA-1 and TIF-2 are now all referred to as SRC-2. It has been
shown through the use of GST pull down assays that SRC-2 interacts with
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the LBD of ER-α in the presence of E2 [70] as well as the AF-1 domain
[71]. Through the use of a transient transfection system, in HeLa cells over
expressing ER-α, it has been shown that SRC-2 stimulates the expression
of the vitellogenin ERE in the presence of E2 [70]. SRC-2 has been shown
to interact with the AF-2 domain and is involved in the ligand mediated
transcription of hormone dependent genes [71].
The following cofactors, ACTR/RAC3/p/CIP/AIB1, are all now referred to
as SRC-3. SRC-3 forms complexes with p300/CBP-associated factor (PCAF)
and may possibly form part of a larger complex containing ER-α, PCAF and
CBP/p300. As with SRC-1 and SRC-2 SRC-3 has an innate HAT activity
[72] and is known to enhance reporter gene expression for many NR’s includ-
ing ER-α (reviewed in [73]).
RIP-140 was first identified in cell extracts from HeLa and COS-1 cells as a
protein that interacted with the ER-α LBD in the presence of E2 [74]. One
of the interesting properties of RIP-140 is that it has a bi-phasic effect of E2
activated ERE driven reporter genes. At low concentrations RIP-140 stimu-
lates transcription whilst at high concentrations it has a repressive effect on
the transcription, all of which is in the presence of E2 [75].
TIF1α was first cloned in mice and interacts with many NR’s including ER-
α in a ligand dependent manner and has been shown to interact with ERE
bound ER-α in the presence of E2 [76]. COS-1 cells that were exposed to
E2 co-expressing ER-α and TIF1α revealed that there was ligand dependent
phosphorylation of TIF1α and that this required binding to transcriptionally
active ER-α [77]. TIF1α also possesses intrinsic kinase activity and selec-
tively phosphorylates TFIIEalpha, TFII28 and TFII55 in vitro. TIF1α may
act as a ER-α co-activator, in part by phosphorylating and modifying the
activity of components of the transcriptional machinery [77].
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p300 and CREB binding protein (CBP) have been identified as co-activators
for class I and class II nuclear receptors [78]. Both CBP (interacts with
SRC-1 [79], SRC-2 [80] and SRC-3 [81]) and p300 interact with SRC-1 and
synergistically enhance ER-α activated reporter gene in transiently trans-
fected cells [79, 82]. CBP is known to interact with the basal transcription
factor TFIIB [83] and interacts with RNA pol II in HeLa extracts which
indicates that CBP interaction with NR co-activator complex may recruit
RNA pol II initiation complex to the promoter [84]. Both p300 and CBP
are known to be acetyltransferases and acetylate all four core histones in
nucleosomes [85, 86]. It has been found that p300/CBP specifically hyper-
acetylates histone H4 of the promoter of E2 responsive genes (PS2, cathepsin
D, c-Myc and EB1) and that after 1 hour acetylation decreases in parallel
with RNA pol II engagement with the promoter. These results indicate that
histone (de)acetylation plays an important role in the E2 induced expression
of sensitive genes [85, 86]. CBP has been known to acetylate SRC-3 and
that this acetylation decreases SRC-3 interaction with E2-ER-α complex in
vitro, which may provide a mechanism in which gene transcription could be
attenuated [77]. CBP interacts with the LBD of ER-α, in the presence of E2,
as well as SRC-1 which suggests that CBP may serve to integrate multiple
signaling pathways in the nucleus [85].
2.5.2 Ligand-independent genomic actions
It is now well established that ER-α mediated transcription can also be
stimulated by ligand independent mechanisms involving second messenger
signaling pathways, which result in the phosphorylation of the ER-α. It
has also been shown that there are cell specific differences in the ability
of secondary messenger pathways to enhance ER-α mediated transcription.
This may be one of the reasons why there are differences in ER-α action in
various cells [87]. This ligand-independent ER-α mediated transcription has
been linked to the AF-1 region of the ER-α [88]. AF-1 activity is enhanced
by the activity of secondary messenger signaling pathways, which supposedly
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relieves the inhibition caused by the LBD. It has also been shown that in
response to ligand, AF-1, synergizes with AF-2 in the LBD and thus also
plays a role in enhancing ligand-dependent, as well as, ligand-independent
transcription via the ER-α.
Phosphorylation sites
Apart from ligand-independent activation of ER-α by phosphorylation, it has
also been shown that the binding of E2 to the ER-α is enhanced by the phos-
phorylation of the ER-α through secondary messenger pathways [89, 90, 91].
There is currently a debate as to whether ER-α is only phosphorylated on
serine residues [89, 90, 91, 92] or whether tyrosine residues are also phos-
phorylated [93, 94]. It does, however, seem that there is not much evidence
for the phosphorylation of tyrosine residues. Though a few cases have been
reported, others have been unable to show tyrosine phosphorylation.
Serine 104, 106, 118 The Serine (Ser) residues 106 and 118 are highly
conserved residues found in many species, whilst Ser 104 is only found in
mammals. All of these residues are located in the AF-1 domain of the ER-α.
It has already been shown that Ser 118 is the major phosphorylation site
in response to E2. It has also been shown that Ser 118 is phosphorylated
in response to MAPK activation by EGF. It has been speculated that Ser
104 and 106 are phosphorylated by different kinases as compared to Ser 118.
This is because the former are phosphorylated by Cyclin A-dependent kinase
2 (Cdk2) whereas the latter is not.
Serine 167 Reports have shown that Ser 167 is a major phosphorylation
site in response to E2 [95], however, controversy surrounds this issue as there
are also reports which do not find this [89]. Serine 167 located in the AF-1
domain is, however, phosphorylated in response to MAPK activation [96]
and it has been found that p90 Ribosomal S6 kinase (Rsk) is responsible for
the phosphorylation [97].
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Serine 236 In vitro it has been shown that Ser 236, located in the DBD of
ER-α, can be phosphorylated by protein kinase A [98].
Tyrosine 537 It has been reported that Tyr 537, located in AF-2 domain,
is phosphorylated and that this phosphorylation is not dependent on the
presence of ligand [93].
Influence on ER-α function
It would seem that the phosphorylation of the serine residues in the AF-1
domain is involved in influencing the recruitment of co-activators which en-
hances ER-α mediated transcription [99, 100, 101]. It has also been shown
that when Ser118 is mutated there is a decrease in the level of transactiva-
tion via the ER-α [97]. Another one of the pathways that is stimulated by
E2, and has important influences on cell biology, is the activation of proline
directed serine/threonine kinase (ERK). ERK is a member of the MAP ki-
nase (MAPK) family. It has been shown that growth factors EGF and IGF
can activate ERK which leads to the phosphorylation of Ser118 in the nu-
clear ER-α [102, 103]. Growth factors are also known to activate pp90rsk−1
via ERK, which results in Ser167 phosphorylation of ER-α [97]. The AF-2
domain plays an important role in mediating transcriptional activation by
cAMP [104]. The importance of this function with respects to ER-α medi-
ated transcription is still being studied. When PKA phosphorylation sites
were removed from ER-α there was no interference of ER-α transcription
via cAMP [105]. This might imply that PKA regulation of the cofactors is
more important than ER-α phosphorylation when looking at ER-α mediated
transcription. It has been noted that in some cases the phosphorylation of
Tyr 537 can result in the ligand independent recruitment of co-activators
thus resulting in constitutively active reporters [106].
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2.6 Factors influencing the levels of transac-
tivation
There a number of factors that can influence the level of transactivation of
estrogenically sensitive genes. These include modulation of the levels of hor-
mones, estrogen receptor levels as well as interaction of co-activators and
co-repressors with the ER-α. In the following section factors that modulate
the levels of ER-α will be discussed.
One of the mechanisms through which the expression of genes The first and
foremost mechanism through which the levels of ER-α expression can be
controlled is through chromatin remodeling. It has been found that the
chromatin has to be unwound before the genes can be transactivated [107].
Another of the mechanisms through which the expression of genes are con-
trolled is through is through the epigenetic regulation of afore mentioned
genes. As an example the levels of ER-α expression are down regulated via
the methylation of the ER-α gene in a number of tissue including colon [108],
lung [109], heart [110], prostrate [111], breast [112] and ovary [113]. In stud-
ies performed using breast cancer tissue it has been found that the level of
ER-α expression is inversely proportional to the level of methylation of ER-α
gene [114]. There is evidence that methylation is not the sole mechanism by
which ER-α levels are controlled. It has been shown that methylation also
involves the assistance of histone deacetylases (HDAC) which remove acetyl
groups from lysine residues on histones H3 and H4, which results in the com-
paction of chromatin [64, 66, 115, 116, 117].
The interaction of cofactors with the promoter region of ER-α is another
mechanism through which the expression of ER-α is regulated. Two tran-
scription factors ER factor 1 (ERF-1) and ER-β factor 1 (ERBF-1) have
been discovered which regulate the levels of ER expression via interaction
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with the promoter of ER-α [118, 119, 120].
The effects that are seen in various tissues can be described by differences
in pharmaco-kinetics, or differential ligand metabolism. It can thus be said
that the same hormone may be present in various tissues, however, the rel-
ative amounts of the hormone in the tissue differ because of altered uptake
or metabolism [107]. All of the above mechanisms can have an indirect reg-
ulation of estrogenic compounds on the transactivation of an estrogenically
sensitive gene.
The role that SHBG plays in regulating the bioavailable levels of estrogen in
the human body will be discussed in the next chapter.
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Sex hormone binding globulin
3.1 Introduction
The bio-availibility of sex steroids are regulated via a number of mecha-
nisms, one of them being the binding of steroids to transport proteins in
plasma. There are two main proteins which bind steroids in human plasma
sex hormone-binding globulin and albumin. Albumin binds sex steroids with
a low affinity and high capacity, while SHBG binds sex steroids with a high
affinity and low capacity. This review will concentrate on the role that SHBG
has in the human body.
It has traditionally been thought that SHBG only regulates the bio-availability
of steroids, however, it has recently been found that SHBG also modulates
hormone action [121].
3.2 Structure
SHBG is a dimeric glycoprotein and was first identified as a β-globulin which
binds E2 and testosterone with a high affinity in human plasma [122]. SHBG
is synthesized in hepatocytes [123] after which it is secreted into plasma
where it binds sex steroids. The SHBG precursor polypeptide consists of
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29 amino acids and a hydrophobic leader sequence followed by 373 residues
that contain two disulfide bridges. In human plasma SHBG is found as a
90 kDa homodimer [124]. SHBG is composed of two laminin G-like domains
which do not require glycosylation to form homodimers. The steroid binding
and dimerization sites of SHBG reside in the amino terminal domain of the
laminin G-like domain. Each monomer of the SHBG homodimer contains a
steroid binding site [125].
The laminin G-like domain of SHBG is comprised of a β-sandwich formed
by seven stranded β sheets. The steroid binding pocket of SHBG, Figure
3.1, is covered by a loop segment which is formed by amino acid residues
130-135 (Pro130, Leu131, Thr132, Ser133, Lys134 and Arg135). This loop
segment functions as a flap that may regulate ligand access to the steroid
binding pocket. In this flap residues 130 and 131 are in an extended confor-
mation. Residues 131 to 134 form a single 310 helical turn with a hydrogen
bond between the main chain carbonyl oxygen atom of Leu131 and the main
chain nitrogen NH group of Lys134. The helical loop segment in this region
of SHBG provides the flexibility needed to allow unhindered access of the
ligand to the ligand binding pocket [125]. The presence of a 17-β hydroxy
group and a planar C-19 steroid with an electro negative group at C3 has
been found to be essential for the optimal binding of a steroid to SHBG,
Figure 3.2. In line with with these criteria, SHBG has the highest affinity
for dihydrotestosterone (DHT), followed by testosterone and finally E2 [126].
Grishkovskya [127] proposed a model for the formation of the SHBG homod-
imer. This model places the β strand 7 of one homodimer next to the β
strand 10 of the second homodimer, which results in the formation of eight
hydrogen bonds being formed within the steroid binding interface. The con-
tact area in the steroid binding pocket is hydrophobic in nature and contains
amino acid residues Ala85, Leu87, Val89, Leu122 and Leu124 [128], Figure
3.1. It has been proposed that only a single steroid molecule is bound by
each SHBG homodimer [129] which would be achieved by the formation of a
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single steroid binding site by two monomeric units [130]. Hammond [131] et
al have proposed that because the steroid binding sites are located so close
to each other, the binding of one site may sterically hinder the binding of
steroid to the other binding site [128]. When observing the SHBG-steroid
bound crystal structure Grishkovskaya [127] noted that both binding sites
were bound, however, also commented that both steroid binding sites may
have been artificially saturated.
Figure 3.1: Steroid binding site of SHBG [125].
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Figure 3.2: Structure of estradiol (E2).
3.3 Regulation
Initially after birth the plasma levels of SHBG in humans are very low but af-
ter a couple of weeks these levels increase dramatically in males and females.
However, at the onset of puberty the levels of plasma SHBG increases even
more dramatically in females [132].
Hormone replacement therapy (HRT) is often used in post-menopausal women
to alleviate the symptoms normally associated with menopause. It is known
that estrogen replacement treatment (ERT) reduces the risk of developing
cardiovascular disease and osteoporosis [133, 134]. There is, however, evi-
dence that there may be a linkage between ERT and breast cancer [135, 136].
It has been shown in HepG2 cells, a human hepatocarcinoma cell line which
expresses SHBG, that 17-β-OH steroids have the ability to increase the lev-
els of SHBG secreted [137]. Clinical trials indicated that, when estrogen
production is increased endogenously or exogenously, there is a concomitant
increase in the levels of SHBG [132, 138, 139], Table 3.2 and Table 3.1.
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Table 3.1: Changes in concentration plasma SHBG in women using
various HRT regimes [140].
Concentration of plasma SHBG (nmol/L)
Pre-treatment Cycle 3 Cycle 6 Cycle 13
CEE/MPA (2.5mg) 36-119 33-175 66-195 18-250
CEE/MPA (5mg) 25-129 33-184 37-242 19-140
Tibolone 25-116 9-61 13-70 13-89
CEE: Conjugated equine estrogens. MPA: medroxyprogesterone ac-
etate. Tibolone is an estrogenic compound that is used in hormone
replacement therapy. The effect of the compounds on the production
of SHBG over a period of 1 year was studied.
Table 3.2: Effect of long term continuous oral and transdermal
estrogen replacement on levels of SHBG [141].
Concentration of plasma SHBG (nmol/L)
Baseline 1 Year 2 Years
Oral 38.6 ± 29.0 74.4 ± 56.2 89.3 ± 57.3
Transdermal 42.1 ± 23.4 41.1 ± 22.4 44.1 ± 28.1
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Studies in HepG2 cells [123] argue against the direct influence of steroids
on the production of SHBG in the liver. Both androgens and estrogens in-
crease, or have little effect, on the levels of SHBG production. The estrogen
induced increase in SHBG levels is more pronounced inside the cell than in
the medium. It is hypothesized that this is due to the production of al-
ternative transcripts and gene products that lack a secretion signal [142]. It
would seem that although sex steroids do not have the ability to affect SHBG
plasma concentration by direct transcriptional mechanisms, they may modify
the carbohydrate composition of the two sub-units [143]. The influence that
sex steroids have on SHBG may thus be to regulate the clearance of SHBG
from plasma [144].
It is known that by eating food high in fiber the levels of SHBG are also
increased because of the presence of phytoestrogens and isoflavanoids, that
have been shown to increase the levels of SHBG in HepG2 cells [142]. In
contrast it has also been shown that, by eating a high fat diet, the levels of
SHBG are decreased [145]. In men there is a correlation between the SHBG
and serum high density lipoproteins (HDL) whilst women, who have low
SHBG plasma levels, are more susceptible to cardiovascular disease.
The relationship between thyroid hormone levels and SHBG is well known.
Patients suffering from thyrotoxicosis have abnormally high thyroid hormone
levels and an enhanced hepatic SHBG production [146]. The elevated plasma
SHBG level is currently being used as one of the possible markers to detect
this disease [146].
Low levels of SHBG are associated with increased triglycerides, decreased
HDL, cholesterol, obesity and other cardiovascular factors. There are con-
flicting results as to how exercise affects serum SHBG levels, Table 3.3. In
some studies no influence [147] has been found on the levels of SHBG while
in other studies an increase [148] or decrease [149] in SHBG levels has been
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found. The following study was designed to determine the effect that a 20-
week endurance exercise program has on the plasma levels of SHBG as well
as familial SHBG levels [150]. It is well known that SHBG transports sex
hormones and that the circulating levels might be regulated differently in
men and women. In the study conducted by Ping et al, [150], levels were
positively associated with estradiol while testosterone and insulin levels had a
negative influence. General adiposity has been shown to increase the produc-
tion of pancreatic insulin, whilst upper body obesity increases the amount of
free testosterone and decreases the clearance of insulin from the liver. This
increase of testosterone and insulin correlates negatively with plasma SHBG
concentrations [151]. In females the concentrations of SHBG and insulin can
be correlated and this relationship can be used to predict the occurrence
of non-insulin dependent diabetes [152]. In males the correlation between
SHBG and insulin is an inverse correlation [153]. Clinical studies have shown
that there is a correlation between hyperinsulinemia, insulin resistance and
SHBG [154]. HepG2 cells have been used to study the regulation of SHBG
production in vitro [155, 156] and it has been shown that both insulin and
insulin-like growth factor had a negative influence on the levels of SHBG
production, Table 3.4, and that this influence was at the RNA level.
Table 3.3: Concentration of SHBG (nM) before and after endurance
exercise [150].
Concentration of SHBG (nM)
Father Mother Son Daughter
Before Exercise 44 ± 17.6 83.8 ± 45.3 35.1 ± 15.0 87.6 ± 47.4
After Exercise -0.1 ± 8.3 -7.9 ± 25.3 -0.1 ± 8.0 -3.4 ± 43.5
(-) indicates a decrease in the levels of SHBG. The levels of SHBG
were measured before and after a 20 week program of endurance
exercise.
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Table 3.4: IGFBP-1 and SHBG RNA calculated in proportion with
ribosomal RNA1
n IGFBP-1 P-value SHBG P-Value
RNA RNA
IGF I (30nM) 4 60± 7.3 0.009 75 ± 3.3 0.025
IGF-II (60nM) 3 48±3.4 0.013 90 ± 3.8 0.20
Insulin (120nM) 2 48± 15 0.034 75 ± 2.9 0.81
1Cited from [157]
3.4 Physiological function
Sex hormone-binding globulin has a high affinity and low capacity for an-
drogens and estrogens [158]. It is believed that one of the main functions
of SHBG is to regulate the amount of free sex steroids in the plasma, and
accordingly the metabolic clearance of these steroids is also influenced. Thus
if SHBG has a high affinity for a sex steroid, the rate at which this steroid
will be cleared from the plasma will be lower than that of a steroid for which
SHBG has a lower affinity for [159, 160].
There are numerous schools of thought as to the function that SHBG plays
in the bio-availability of steroids in the human body. The free hormone hy-
pothesis states that only the portion of steroid that is free, i.e. unbound,
is biologically active as only the free steroids can enter the cell by simple
diffusion [1]. This hypothesis has been challenged by many authors such as
Siiteri [159] and Padridge [161] with respect to the role that extracellular
binding proteins such as SHBG play. There are two arguments which have
been used both of which argue against the hypothesis that only free steroids
are biologically active. The first argument proposed by Siiteri [162] states
that when considering the concentration of SHBG and circulating amount of
E2 at any stage during the menstrual cycle, there would not be enough free
steroid to fully occupy cellular estrogen receptors, which is a requirement
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for maximal estrogen response. The second argument proposed by Padridge
[161] states that if the pool of free hormone accounted for all the action of
sex steroids, then all tissues would be exposed to the same level of hormones.
Padridge also suggested that the SHBG bound steroid is available to cells
and that SHBG could release steroids at the site of action and amplify the
steroid effect where needed. As a result of this research it is now known that
SHBG can bind a membrane bound receptor in cells that are sensitive to the
presence of sex steroids. This binding of the SHBG to the membrane receptor
is thought to play a role in guiding sex steroids to the site of their action [163].
Epidemiological evidence has shown that the risk of developing breast can-
cer is related to the amount of time that a woman is exposed to ovarian
estrogens and progestins [164, 165]. Post-menopausal estrogen replacement
therapy (ERT) or hormone replacement therapy (HRT), which contains estro-
gens and progestins, is related to the development of breast cancer [166, 167].
Both obesity [168] and hyperinsulinemia have been identified as risk factors
for developing breast cancer [169] because they affect estrogen metabolism
and decrease the binding of estrogens to SHBG.
A membrane SHBG-receptor has been identified which is thought to be in-
volved in the control of proliferation of breast cancer cells, via a cAMP cas-
cade pathway [170, 171, 172]. A New York Women’s Health study has shown
that an increase in free and total E2, with a decrease in SHBG-bound E2,
results in an increase of breast cancer incidences in post-menopausal women
[168, 173, 174].
It is well known that coronary heart disease (CHD) is often positively as-
sociated with serum levels of DHEAS and free testosterone in women. The
association of SHBG with coronary heart disease is not well known but it is
known that low levels of SHBG are associated with low levels of high density
lipoproteins (HDL), cholesterol and high levels of triglycerides, apoprotein B
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and free testosterone, all of which are known to coincide with coronary heart
disease [175, 176]. In support of this it has been found that post-menopausal
women with CHD have a low serum concentration of SHBG [177].
The role that SHBG plays in the regulation of the bioavailable levels of es-
trogens in the human body has been described. The next chapter describes
the results obtained using the experimental systems described in Chapter 1.
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Chapter 4
The influence of SHBG on E2
binding by the ER-α: An
experimental approach
As stated in the introduction the aim of this project was to develop an ex-
perimental system to describe the binding of E2 to the human ER-α in the
absence or presence of SHBG. The secondary aim was to determine what
effect SHBG had on the transactivation of an ERE, via the ligand bound
ER-α. The final aim of this project was to build a mathematical model that
would describe the above mentioned conditions. A number of variables are
needed to build the mathematical model. The variables that are needed are
shown in Table 4.1.
To achieve these aims a number of experimental systems are needed so as
to obtain the binding constants (Kd (E2) and Bmax) for ER-α in the absence
and presence of SHBG, as well as data from the transactivation studies. The
binding constants for SHBG binding E2, Kd and Bmax in the absence of ER-α
are also required.
The experimental systems used for this approach were three fold:
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• COS-1 cells were used as an experimental system in which data on the
binding of E2 to ER-α, in the absence of SHBG, as well as data from
transactivation studies could be collected, Figure 4.1.
• Hep89 cells were used for similar experiments except that SHBG is
endogenous in these cells. As such the data collected would show the
effect that SHBG has on the binding of E2 to ER-α and the transac-
tivation of an ERE, via the ligand bound ER-α. As Hep89 cells were
stably transfected with ER-α it was not necessary to transfect these
cells with the human ER-α gene, Figure 4.2.
• Human pregnancy plasma contains high levels of SHBG. By using sat-
uration binding assays it should be possible to determine the kinetic
binding constants (Kd and Bmax) for the binding of E2 to SHBG.
Table 4.1: Parameters needed to build the mathematical model of
agonism.
Binding proteins Binding constants
hER-α Kd (E2) (intracellular)
Bmax (ER-α) (intracellular)
hSHBG Kd (E2)
Bmax (SHBG) (intracellular and extracellular)
Volume of compartments Experimental system
Cytoplasm COS-1 and Hep89 cells
Medium COS-1 and Hep89 cells
Metabolic studies Experimental system
Metabolism of E2 COS-1
Metabolism of E2 Hep89
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Nucleus
ERE
Transactivation
Estrogen receptor
Estrogen
Cell membrane
Figure 4.1: Diagram of the experimental system when only E2 and
ER-α are present. In this experimental system E2 can be transferred across
the cell membrane and bind to ER-α. The nucleus and cytoplasm have been
defined as one compartment.
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SHBG
ERE
Transactivation
Estrogen receptor
Cell membrane
Nucleus
Estrogen
Figure 4.2: Diagram of the experimental system when E2, ER-α and
SHBG present. This system describes the situation where E2 can bind to both
ER-α as well as SHBG. The binding of E2 to SHBG has been defined as occurring
in the medium and inside the cell, while E2 can be transported into the cell and
bind ER-α. The nucleus and cytoplasm have been defined as one compartment.
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4.1 Development of an experimental system
for E2 binding
4.1.1 COS-1 cell system
Optimisation of binding
The aim of the following experiments was to determine the binding constants,
Kd and Bmax of hER-α when binding E2 in COS-1 cells in the absence of
SHBG. The experimental approach used to obtain the required data was to
transfect COS-1 cells with the hER-α gene and then to perform competitive
binding experiments. The experimental system was initially optimised by
varying the amount of hER-α that the COS-1 cells were transfected with.
After the amount of hER-α to be used was optimised the amount of 3H-
E2 that would be used in the experimental procedure had to be optimized.
The reason that the amount of 3H-E2 had to be optimized was as follows:
To determine the Kd using the competitive binding experimental system the
amount of 3H-E2 used had to be between two and ten times lower than the
IC50 E2 . The IC50 E2 is defined as the concentration of unlabelled ligand that
reduces the Specific binding of labelled ligand by 50%. By using this informa-
tion the relationship between the Kd (E2) and IC50 E2 can be mathematically
defined.
0.5
Bmax (ER-α).[
3H-E2]
[3H-E2] + Kd (E2)
=
Bmax (ER-α).[
3H-E2]
[3H-E2] + [E2] + Kd (E2)
(4.1)
Equation 4.1 can be simplified to:
IC50 = [
3H-E2] + Kd (E2) (4.2)
As can be seen when determining the Kd if the IC50 E2 is less than the amount
of labelled compound (3H-E2) the results of this calculation would yield a neg-
ative Kd, which is not possible.
The aim of the following experiments was to determine minimal and maximal
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amounts of pcDNA3-ER-α to be used in binding experiments and the lev-
els of Specific binding that could be expected. COS-1 cells were transiently
transfected with either 0.012µg or 0.102µg of pcDNA3-ER-α and exposed to
20nM 3H-E2. In determining the Specific binding the transfected COS-1 cells
were exposed to two conditions:
• COS-1 cells were exposed to 20nM 3H-E2 whilst using 1×10−5M E2
as a competitor. This would allow the determination of Non Specific
binding.
• COS-1 cells were exposed to 20nM 3H-E2 whilst using ethanol as a
competitor. This would allow the determination of Total binding.
Specific binding, that is the binding was determined as follows:
Specific binding = Total binding− Non Specific binding (4.3)
The results of this experiment, Figure 4.3, show that maximal specific binding
was obtained when COS-1 cells were transfected with 0.102µg pcDNA3-ER-α
and minimal specific binding (about 2000 cpm) when 0.012µg of pcDNA3-
ER-α was used. It was decided that in future 0.52µg of pcDNA3-ER-α would
be used to transfect COS-1 cells as it would then be possible to transfect with
a β-galactosidase and ERE reporter gene when performing transactivation
studies. This method would enable the transfection of COS-1 cells and use
these cells for both binding and transactivation studies.
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Figure 4.3: Optimization of amount of pcDNA3-ER-α to use in
binding experiments. COS-1 cells were transiently transfected with either
0.012µg (12%) or 0.102µg (96%) pcDNA3-ER-α plasmid as described in
Appendix C.3.2. COS-1 cells were then exposed to 20nM 3H-E2 in the presence
of either ethanol (Total binding) or 1×10−5M E2 (Non Specific binding) for 10
hours. Ligand binding was determined as described in Appendix C.5.2. Results
are shown as the standard error of the mean of triplicate samples. Specific
binding was calculated as Total binding - Non Specific binding.
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Competitive binding assay The aim of the following experiment was to
determine the amount of 3H-E2 that should be used in competitive binding
assays. Competitive binding assays were used to determine the Kd and Bmax
of hER-α when binding E2 in the absence of SHBG. The experimental con-
ditions used were optimised by varying the amount of 3H-E2 (10nM, 1nM,
0.5nM and 0.1nM). From the results of this experiment, Figure 4.4, it can
be seen that maximal Specific binding was obtained when 10nM 3H-E2 was
used and that minimal specific binding was obtained when 0.1nM 3H-E2 was
used. When examining the results it was noted that when 1nM of 3H-E2 was
used a Specific binding of roughly 1800 cpm was obtained and it was decided
that in future 1nM of 3H-E2 would be used in future competitive binding
assays.
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Figure 4.4: Optimisation of the amount of 3H-E2 used in binding
experiments. COS-1 cells were transfected using 0.52µg pcDNA3-ER-α, 0.10µg
ERE-vit, 2.34µg pGL-2-Basic and 0.12µg pCMV-β-galactosidase as described in
Appendix C.3.2. COS-1 cells were then exposed to varying amounts
concentration of 3H-E2 (10nM, 1nM, 0.5nM and 0.1nM) in the presence of either
ethanol (Total binding) or 1×10−5M E2 (Non Specific binding) for 10 hours.
Ligand binding was determined as described in Appendix C.5.2. Results are
shown as the standard error of the mean of triplicate samples. Specific binding
was calculated as Total binding - Non Specific binding.
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Whole cell binding of E2 to the hER-α in COS-1 cells
The aim of the following experiments was to determine the Kd and Bmax for
hER-α binding E2 in the absence of SHBG. This was accomplished perform-
ing competitive binding assays, using COS-1 cells, to determine the IC50 E2
and to use this to determine the Kd (E2) for hER-α.
COS-1 cells were transfected with pcDNA3-ER-α, as described in Appendix
C.3.2, after which competitive binding assays were performed using 1nM 3H-
E2 in the presence of varying amounts of E2 (between 1×10−5 M to 1×10−13
M) or ethanol. From the results of this experiment, Figure 4.5, it was de-
termined that the IC50 E2 was determined as 2.35×10−9 M, using a one site
binding equation [178]. As the IC50 E2 was greater than twice the amount
of 3H-E2, 1nM, used the Kd could be determined using these results. The
Kd (E2) was determined as between 3.45nM and 4.4nM using a homologous
competitive binding model equation [178]. The Kd (E2) that was determined
using this experimental system is not similar to that which Kupier [49],
Kd (E2) = 0.1nM, determined using a pure ER-α solution, however is sim-
ilar to that which Pederson [179] determined, between 2nM and 4nM, from
human fat samples. With respect to the determination of Bmax (ER-α) it was
determined that the Bmax (ER-α) was between 1.42nM and 2.62nM a one site
binding equation [178] and the quick calculations from the Graphpad website
(http://www.graphpad.com/quickcalcs/radcalcform.cfm).
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Figure 4.5: Competitive binding assay using COS-1 cells. COS-1 cells
were transfected using 0.52µg pcDNA3-ER-α, 0.10µg ERE-vit, 2.34µg
pGL-2-Basic and 0.12µg pCMV-β-galactosidase as described in Appendix C.3.2.
COS-1 cells were then exposed to 1nM 3H-E2 in the presence of either ethanol
(Total binding) or varying amount of E2 (1×10−5M to 1×10−13M, Non Specific
binding) for 10 hours. Ligand binding was determined as described in Appendix
C.5.2. Results are shown as the standard error of the mean of triplicate samples.
Specific binding was calculated as Total binding - Non specific binding. The
IC50 E2 was determined as 2.35×10−9M and the Bmax (ER-α) as between 1.42nM
and 2.62nM.
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4.1.2 Optimisation of E2 binding in Hep89 cells
The aim of the following experiment was to determine the effect that SHBG
had on the binding of E2 to hER-α. To accomplish this, competitive binding
and saturation binding assays were undertaken to determine the Bmax app (ER-α)
and Kd app. The experimental approach was to use Hep89 cells which have
been stably transfected with hER-α and endogenously produce SHBG. Ini-
tially competitive binding assays were used, however, as will be explained
problems were encountered and saturation binding assays performed.
Competitive binding assay
As stated the aim of these experiments was to determine the Bmax app and
Kd app for E2 binding ER-α in the presence of SHBG. Hep89 cells were seeded
and grown as described in Appendix C.5.3 after which the cells were exposed
to 1nM 3H-E2 in the presence of varying concentrations E2 (1×10−5M to
1×10−13M) or ethanol. From the results of this experiment, Figure 4.6, it
was determined that the IC50 app E2 was 7.52×10−12M. As has been stated
the IC50 E2 has to be between two and ten times more than the amount of
3H-E2 or the Kd would be negative. As the IC50 app E2 was about 132 times
smaller than the amount of 3H-E2 used it was not possible to determine the
Kd app from the results of these experiments. There are two suggestions as
suggested by literature [178] in which this problem can be overcome. The
first possibility being that the labelled ligand (3H-E2) and the unlabelled
ligand (E2) bind the receptor (hER-α) with different affinities. This is not
a likely option as both the labelled and unlabelled ligand are both 17-β-
estradiol. The second option is to lower the amount of labelled ligand used
in the experiment significantly. It should be noted from the results, Figure
4.6, that maximal binding occurred at roughly 925 cpm. If the amount of 3H-
E2 used in the experiment was lowered then the number of cpm at maximal
and minimal binding would be so low that Poisson distribution would have to
be taken into account. Poisson distribution is a term that is used to describe
the decay of a population of radioactive atoms and the sampling error that
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arises during measuring the decay. The sampling error can be determined
through the following equation:
100× 1.96×√C
C
=
196√
C
(4.4)
Where C = cpm multiplied by the number of minutes that the sample was
counted. Using this data it is possible to calculate that if the number of cpm
is below 500 there is a large error intrinsically present in sampling [178]. Be-
cause of the problems associated with this experimental system it was decided
that saturation binding assays would be used to determine Bmax app (ER-α) and
Kd app (E2).
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Figure 4.6: Competitive binding assay using Hep89 cells to determine
the effect that SHBG has on the Bmax app (ER-α) and Kd app (E2). Hep89
cells were seeded and grown as described in Appendix C.5.3. The cells were then
exposed to 1nM 3H-E2 in the presence of ethanol (Total binding) or varying
concentrations E2 (1×10−5M to 1×10−13M). Ligand binding was determined as
described in Appendix C.5.2. The IC50 app E2 was determined as 7.52×10−12M
using a one site competitive binding function [178]. Results are shown as the
mean and standard error of the mean for triplicate samples.
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Saturation binding assay
The aim of the following experiment was to determine the Kd app and Bmax app
for E2 binding hER-α in the presence of SHBG. The experimental approach
used was to perform a saturation binding assay using Hep89 cells as the
experimental system. Hep89 cells were seeded and grown as described in
Appendix C.5.3 after which they were exposed to varying amounts of 3H-E2
(between 0.25nM and 30nM) in the presence of 1×10−5M E2 (Non Specific
binding) or ethanol (Total binding). The results of this experiment, Figure
4.7, showed that there was ligand depletion, Table 4.2.
Table 4.2: Ligand depletion encountered during saturation binding
using Hep89 cells.
Total Total Percentage
added (cpm) binding (cpm) ligand depletion (%)
73460 23544 29
60540 12649 19
31060 4350 15
17700 2262 12
12300 1897 14
8520 1226 15
7760 763 9
4200 618 13
3000 429 13
Ligand depletion calculated as (Total binding/total added)×100.
Ligand depletion is defined as the condition under which more than 10%
of the labelled ligand, 3H-E2, is bound in the experimental system in the
absence of competitor. Because of the presence of ligand depletion the re-
sults of this experiment had to be analyzed using an equation that accounts
for the presence of ligand depletion equation 4.5 [178]. The results of this
48
4.1 Development of an experimental system for E2 binding
analysis showed that it was not possible to determine the Bmax app (ER-α) and
Kd app (E2).
Total binding =
−b +
√
b2 − 4ac
2a
Non Specific binding = X.
(
NS
NS + 1
)
(4.5)
Where:
a = -1 -NS
b = X(2-NS+1) + Kd(NS+1) + Bmax
c = -X(NS(Kd + X) + Bmax)
NS = Non Specific binding (cpm) in the presence of an excess of unla-
belled compound
X = Concentration labelled ligand (cpm)
Kd = Equilibrium disassociation constant (cpm)
Bmax = Maximal density of receptor binding sites for radioligand (cpm)
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Figure 4.7: Saturation binding assay using Hep89 cells to determine
the effect that SHBG has on the Bmax app (ER-α) and Kd app (E2). Hep89
cells were seeded and grown as described in Appendix C.5.3. The cells were then
exposed to varying amounts of 3H-E2 (between 0.25nM and 30nM) in the
presence of ethanol (Total binding) or 1×10−5M E2 (Non Specific binding).
Ligand binding was determined as described in Appendix C.5.2. The results were
fitted to an equation that accounted for the presence of ligand depletion equation
4.5 [178]. Results are shown as the mean and standard error of the mean for
triplicate samples.
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4.1.3 Binding of E2 to SHBG in human pregnancy
plasma
The aim of the following experiments was to determine the Kd and Bmax (SHBG)
for SHBG binding E2. To determine the Kd (E2) competitive and saturation
binding experiments were performed using human pregnancy plasma as an
experimental system. Human pregnancy plasma was used because it contains
high amounts, up to 420nM [180], of SHBG. The experimental system used
was based on that of Hammonds [180].
Optimisation of experimental system
The aim of the following experiment was to determine whether Dextran
coated charcoal (DCC) could be used to remove endogenous and unbound
steroids from human pregnancy plasma. The removal of endogenous steroids
was important because if any endogenous steroids remained they might have
a negative influence on the binding of E2 to SHBG.
The effect of the presence of endogenous steroids was studied by compar-
ing samples that had been exposed to DCC before and after the addition
of 3H-E2 to samples that had only been exposed to DCC after the addition
of 3H-E2. The ability of DCC to remove any unbound steroids was studied
by comparing samples that contained no SHBG but either contained 3H-E2
or no ligand and then exposed to DCC. The results of this experiment are
shown in Figure 4.8. With respect to the ability of the effect of endogenous
steroids it can be seen that the removal of these endogenous steroids does
have an effect. This can be seen when comparing the total binding of the
samples labelled “DCC before/after”, maximal binding 24309 cpm to “SHBG
+ DCC after”, maximal binding 24524 cpm as well as the samples “SHBG +
DCC before”, maximal binding 163604 cpm, and “No DCC”, maximal bind-
ing 164001 cpm. By comparing the samples “No SHBG and DCC”, maximal
binding to “No SHBG and No DCC” it is possible to see that DCC does
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remove any unbound steroids.
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Figure 4.8: Optimisation of conditions for binding of 3H-E2 using
human pregnancy plasma as an experimental system. Human pregnancy
plasma was prepared as described in Appendix C.6. The samples were then
exposed to 20nM 3H-E2and either 10−5M E2 (Non Specific binding) or EtoH
(Total binding) was added to the samples after which the samples were incubated
for 10 hours. Error bars indicate the standard error of the mean for triplicate
determinations.
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Competitive binding assay
The aim of the following experiment was to determine the Kd for E2 binding
SHBG in the absence of ER-α. Human pregnancy plasma was prepared as de-
scribed in Appendix C.6 after which the samples were exposed to 1nM 3H-E2
in the presence of varying amounts of E2 (between 1×10−5M and 1×10−13M)
or ethanol.
From the results of this experiment, Figure 4.9, it was determined that the
IC50 E2 was 1.09×10−7M. As has been described before, to determine the
Kd using this method the IC50 E2 has to be between two and ten times the
amount of 3H-E2, in this case 1nM, used. As this was not the case it was
decided to determine the Kd (E2) using a saturation binding assay.
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Figure 4.9: Competitive binding assay using human pregnancy plasma
as a source of SHBG. Human pregnancy plasma was prepared as described in
Appendix C.6 after which 1nM 3H-E2 was added to the samples in the presence
of varying amounts (between 1×10−5M and 1×10−13M) or ethanol and the
samples incubated for a further 10 hours. Ligand binding was determined as
described in Appendix C.5.2. The IC50 E2 was determined as 1.09×10−7M by
fitting a one site binding equation [178] to the data. Results are shown as the
mean of the triplicate samples with standard errors.
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Saturation binding assay
The aim of the following experiments was to determine the Kd for SHBG
binding E2 in the absence of ER-α. Initially the experimental system was
optimized for the amount of SHBG present by varying the dilution ratio of
the human pregnancy plasma. This optimisation was aimed at determining
how much the plasma should be diluted to obtain the highest Specific binding.
The optimisation of the system was accomplished by diluting human preg-
nancy plasma 100, 50 or 25 times, as described in Appendix C.6, whilst
maintaining the same ratio between DCC and plasma. It is known that the
Kd for SHBG is 1.5nM [158] and thus SHBG should be saturated in the
presence of 15nM E2. Using this information it was decided that 30nM of
3H-E2 would be used as this would ensure the saturation of SHBG binding
sites. The results of this experiment, Figure 4.10 , showed that the highest
Specific binding roughly 7500 cpm was obtained when the pregnancy plasma
was diluted 25 times.
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Figure 4.10: Optimisation of the conditions for saturation binding
using human pregnancy plasma. Human pregnancy plasma was diluted, as
described in Appendix C.6, either 100; 50 or 25 times, whilst maintaining the
same ratio between DCC and plasma. After the samples had been prepared
30nM of 3H-E2 was added in the presence of 1×10−5M E2 (Non Specific binding)
or ethanol (Total binding) and the samples incubated for 10 hours. Ligand
binding was determined as described in Appendix C.5.2. Specific binding =
Total binding - Non Specific binding. The results are shown as the average mean
with standard errors for triplicate samples.
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The aim of the following experiment was to determine the Kd for SHBG
binding E2 in the absence of ER-α. Human pregnancy plasma was diluted
25 times and prepared as described in Appendix C.6. The samples were then
exposed to 30nM 3H-E2 in the presence of either 1×10−5M E2 (Non Specific
binding) or ethanol (Total binding). The results of this experiment, Figure
4.11, show that there was ligand depletion, Table 4.3.
Table 4.3: Ligand depletion encountered during saturation binding
using human pregnancy plasma.
Total Total Percentage
binding (cpm) Added (cpm) ligand depletion (%)
130628 371600 35
71220 194817 37
27947 75232 37
16258 40363 40
10784 29713 36
6878 18427 37
4658 13012 36
3564 9649 37
2349 6649 35
1838 5819 32
1878 4338 43
Ligand depletion calculated as (total binding/total added)×100.
As has been described it is possible to determine the Kd for SHBG binding
E2 in the presence of ligand depletion by fitting a function which accounts
for the presence of ligand depletion. It was, however, not possible to deter-
mine the Kd (E2) for SHBG using this function. It should be noted that in
other publications it has been possible to determine the Kd for SHBG binding
E2 using a solid phase assay [158]. Hammond [181] used a similar experi-
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mental system, to the one employed in these experiments, to determine the
Kd (dihydrotestosterone) for SHBG as was successful. The possible reasons why
this experimental system did not work will be discussed later in Chapter 6.
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Figure 4.11: Saturation binding assay using human pregnancy plasma.
Human pregnancy plasma was diluted 25 times and 30nM 3H-E2 in the presence
of either 1×10−5M (Non Specific binding) or ethanol (Total binding) was added.
Ligand binding was determined as described in Appendix C.5.2. Due to the
presence of ligand depletion Table 4.3 data was fitted with a function that
accounts for ligand depletion and results graphed as Total binding (cpm) vs
Total added (cpm). Results are shown as the mean of triplicate samples with
standard errors.
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4.2 Development of experimental system for
promoter reporter gene assay studies
As stated in Chapter ?? one of the aims of this project was to determine the
effect that SHBG has on the transactivation of an ERE via the ligand bound
ER-α. To determine the effect of SHBG on the above mentioned interaction
the following experimental approach was used:
• COS-1 cells were used to determine the transactivation of an ERE, via
the ligand bound ER-α, using promoter reporter gene assays.
• Hep89 cells were used to determine the effect that SHBG had on the
transactivation of an ERE, via ligand bound ER-α.
The aim of the following experiment was to determine the level of transacti-
vation of an ERE in COS-1 cells. The experimental system was optimized for
the use of various medium supplements; fetal calf serum, stripped fetal calf
serum, no fetal calf serum. The rationale for the use of these supplements
was to determine whether fetal calf serum contained any endogenous steroids
that might interfere with the assay. The use of a DMSO during transfection
was also studied as it has been suggested that a DMSO shock may increase
transfection efficiency [182].
The results of this experiment, Figure 4.12, showed that DMSO did not
have a significant effect as can be seen when comparing the samples exposed
to a DMSO shock to those not exposed. With respect to the use of various
medium supplements it was noted that there highest level of transactivation
was obtained when COS-1 cells were not DMSO shocked and fetal calf serum
was used as a medium supplement. The lowest levels of transactivation were
obtained when no fetal calf serum was used. This would seem to indicate
that endogenous steroids present in fetal calf serum may have an influence
on the transactivation of an ERE. The promoter reporter gene assays per-
formed in COS-1 cells were to be the control for the absence of SHBG. As
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there was ligand independent transactivation, compare samples exposed to
E2 to those exposed to ethanol, it was decided to not continue with the
promoter reporter studies in the presence of SHBG. The presence of ligand
independent transactivation in these experiments is in contradiction with the
results of Pennie et al [183] who stated that there was no ligand or receptor
independent transactivation of a vitellogenin ERE in COS-1 cells. One of the
possible reasons may be the use of the specific ERE in these experiments,
which was designed for use in HepG2 cells.
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Figure 4.12: Optimization of transactivation in COS-1 cells. COS-1 cells
were transfected with an ER-α, ERE-vitellogenin reporter gene and a
β-galactosidase (ratios used were those of Stoica C.3 in Appendix C.3.1) reporter
using the DEAE-Dextran transfection method as described in Appendix C.4.
The use of various medium supplements (fetal calf serum, stripped fetal calf
serum and no fetal calf serum) was studied as well as the role of a DMSO shock
during transfection. Results are shown as the average of triplicate samples with
standard errors.
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4.3 Metabolic studies
The aim of the following experiments was to determine whether there was
any metabolism of E2 in COS-1 cells and Hep89 cells. The reason for this is
Hep89 cells, which were derived from a liver carcinoma, may have enzymes
present that could metabolize E2.
4.3.1 Separation of steroids using thin layer chromatog-
raphy
The experimental protocols that were used to determine whether E2 was me-
tabolized in COS-1 cells or Hep89 cells relied on exposing the cells to 3H-E2
for a period of either 1 or 10 hours as described in Appendix C.7. The cells
were then lysed and the steroids extracted using dichloromethane as a sol-
vent. As a control for extraction efficiency the samples were “spiked” with
a known amount of 3H-Dexamethasone. After the extraction the amount of
3H-Dexamethasone could be compared to the amount added and this would
give an indication of the extraction efficiency. The results of these experi-
ments are shown in Figure 4.13 and Figure 4.14. From these results it was
concluded that there was no metabolism of E2 after either 1 hours or 10 hours.
This was determined by comparing the samples from COS-1 or Hep89 cells
after either 1 or 10 hours.
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Figure 4.13: Metabolic studies in COS-1 and Hep89 cells COS-1 and
Hep89 cells were exposed to 1µl of 3H-E2 for a period of 1 hour. The cells were
lysed after which 1ml of the samples was added to 5ml dichloromethane. To
account for extraction efficiency the samples were “spiked” with 1µl of
3H-Dexamethasone. The samples were prepared as described in Appendix C.7,
after spotting on a thin layer chromatography plate the samples were run for one
and a half hours in the presence of a 70% chloroform and 30% acetone solution.
The amount of 3H-E2 and 3H-Dexamethasone was determined as described in
Appendix C.7 and the results normalized using the extraction efficiency of
3H-Dexamethasone. Extraction efficiency for 3H-Dexamethasone was calculated
as the amount of 3H-Dexamethasone retrieved over amount added. Results are
shown as the average with standard errors for duplicate samples.
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Figure 4.14: Metabolic studies in COS-1 and Hep89 cells The
experiment was performed as described in Figure 4.13. Results are shown as the
average with standard errors for duplicate samples.
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4.4 Determination of amount of SHBG in Hep89
cells
Hep89 cells were seeded and grown as described in Appendix C.8. The results
of this experiment were inconclusive because no detectable SHBG was found
in either the extracellular or intracellular samples. Although SHBG has
been found in HepG2 cells (± 21.4 nmol/L) [137], as of yet there has been
no determination of SHBG levels in Hep89 cells. One of the reasons for the
failure to detect SHBG in either the extracellular or intracellular samples may
have been that the protein in the samples may not have been in solution,
however, further experimentation will be needed to determine this.
4.5 Determination of cell volumes
The volume of the extracellular medium and intracellular medium was de-
termined for COS-1 cells as described in Appendix C.9. From the results of
this experiment it was determined that the extracellular volume was 0.001L
and the intracellular volume was 5.96×10−6L.
The various models that currently exist to describe the interactions of es-
trogenic compounds with the estrogen receptor will be described in Chapter
5.
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Chapter 5
Mathematical and descriptive
models
5.1 Operational model of agonism
Bio-assays are used in quantitative pharmacology to estimate the pharmaco-
logical properties of compounds. These bio-assays measure and quantify the
physiological response to a pharmacologically active compound. To quantify
the pharmacological properties of a pharmaco-active substance the bio-assays
have to be designed in such a way that they are comparative, or “null meth-
ods”, so as to eliminate secondary physiological information.
A brief history of the events that led to the development of the operational
model of agonism follows. One of the simplest bio-assays developed, to mea-
sure physiological response, was a dilution assay in which a compound, known
to have a physiological response, was titrated against a known standard of the
same compound. This method was useful to determine the concentrations,
of a pharmaco-active compound, that was needed to initiate a physiological
response. When analyzing simple competitive antagonism, which is also a
form of a dilution assay, a number of assumptions about the nature of the ac-
tion of agonist and antagonist are needed. It is assumed, in these bio-assays,
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that both agonist and antagonist interact with common tissue components
and receptors. These interactions are said to be governed by the law of mass
action and the antagonist receptor interaction can be characterized by a sin-
gle binding parameter.
The physiological effect can be equated with fractional occupancy and a sin-
gle binding parameter, which itself is characterized by the receptor agonist
complex. This information has led to the concept of “full” and “partial” ago-
nism [184]. The concept of “full” and “partial” agonists was first noted when
it was seen that different agonists would elicit different maximal responses
when associating with the same receptor whilst still in the same tissue. In
response to this Arins introduced a proportionality term between effect and
fractional occupancy. This proportionality term was assumed to be agonist
determined, however Stephenson [185] altered the model when it was noted
that the pharmacological effect was not necessarily proportional to fractional
occupancy.
In his model Stephenson proposed that agonists produced equal effects by
evoking equal stimuli in a tissue. The concept of stimulus, the product of
traditional occupancy and a parameter efficacy was introduced. Efficacy was
defined as the power of the agonist to elicit a response. Stephenson also re-
lated effect to stimulus through a monotonic function that was dependent on
the tissue and the agonist. Using this concept it was thus possible to describe
why the same agonist had a different response in various tissues and that a
maximal response could be elucidated at sub-maximal receptor occupancy.
The model that Stephenson proposed was revised and modified by Furchgott
[186].
In the model Furchgott introduced the concepts of initial concentration of ac-
tive receptors and intrinsic efficacy. Intrinsic efficacy is defined as the purely
agonist dependent part of efficacy and thus the traditional theory of efficacy
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was divided up into two parts:
• The agonist dependent part which is defined by the affinity KA and
intrinsic efficacy (ε).
• The tissue dependent part which is defined by receptor concentration
(Ro) and the stimulus effect (E/S) relation.
There are however a number of problems with the current traditional model.
In the assays it is assumed that tissue dependent information is canceled out
and thus the KA and ε would become estimable. Mackay [187] has shown
that it is theoretically impossible to estimate absolute values of ε and that
only relative values, for different agonists, are measurable. With respect to
the determination of KA for partial agonists, using full agonists in the same
system, it is only possible to do so if an extreme ratio of intrinsic efficacies
is assumed.
With these problems in mind Black and Leff [188] developed a general opera-
tional model of agonism which expressed pharmacological effect as an explicit
function of agonist concentration.
5.1.1 General operational model of agonism
The effect of hormones, and other agonists, can only be recognized in physio-
logical, intact tissue, systems. A hormone-tissue pair can be characterized by
determining response as a function of agonist concentration and is quantified
using the E/[L] function, where E is the effect and [L] is the concentration of
ligand. Most E/[L] curves are monotonically increasing functions of [L] that
involve a minimum of three parameters:
• Maximal response generated by saturating [L]
• IC50 is the value of ligand at half maximal response
• The slope of the E/[L] curve at half maximal response
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Black and Leff developed a model for operationally hyperbolic E/[L] curves.
In the traditional theory it is assumed that an agonist, L, binds to receptors,
R, and that this reaction obeys the laws of mass action. At equilibrium the
concentration of occupied receptors depends on the [L] and Kd.
Using Furchgott’s [186] convention it is possible to determine that the con-
centration of liganded receptors [LR], depends on the total concentration of
receptors [Rtot], the equilibrium concentration of ligand, [L], and the Kd.
[LR] =
[Rtot] [L]
Kd + [L]
(5.1)
The chemical reaction can be represented as follows:
R + L
kon

koff
RL (5.2)
The law off mass action as formulated by Guldberg and Waage states that
the rate of a chemical reaction is proportional to the concentration of the
individual species involved in the chemical reaction [189]. Using the chemical
reaction, equation 5.2, it is possible to determine the Kd via derivation of the
rate at which the ligand receptor complex is formed, kon, and disassociates,
koff, if one assumes equilibrium.
Von = kon[R][L]
Voff = koff[LR]
(5.3)
At equilibrium Von = Voff
koff
kon
=
[R][L]
[LR]
= Kd (5.4)
The total amount of receptor can be determined in terms of bound and
unbound receptor.
[Rtot] = [LR] + [R] (5.5)
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By combining the equations 5.5 and 5.4 it is possible to describe the amount
of bound receptor as follows, which is the same as equation 5.1:
[LR] =
[Rtot][L]− [LR][L]
Kd
[LR].Kd = [Rtot][L]− [LR][L]
[LR].Kd + [LR].[L] = [Rtot][L]
[LR] =
[Rtot].[L]
Kd + [L]
(5.6)
When [L] [Rtot] it is assumed that the amount of free ligand at equilibrium
is the same as the amount of ligand added initially. By using this assumption
it is possible to derive a function that relates the concentration of ligand
bound receptor to a physiological response (E).
E = z([LR]) (5.7)
By combining equations 5.9 and 5.6 it is possible to mathematically describe
the E/[L] relationship.
E = z
(
[Rtot][L]
Kd + [L]
)
(5.8)
A function for z must still be found which can be used to describe experi-
mental hyperbolic curves. The function z can be regarded as a transducer
function that conveys occupancy ([LR]) into an effect, E. Black and Leff were
able to show that there were only two choices available to describe the E
[LR]
relation: either linear or hyperbolic.
If the transducer function, z, were a straight line then E would be propor-
tional to [LR]. If this was so then IC50 would equal Kd for every agonist and
no receptor reserve would exist. This option has been ruled by experimen-
tal results in which different agonists exert maximal pharmacological effect
under different occupancy values. The only other choice is to describe the
transducer function as a rectangular hyperbolic function of [LR].
E
Emaximal
=
[LR]
KE + [LR]
(5.9)
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Where:
• Emaximal is the maximal response
• KE is the value of [LR] that elicits half maximal response
By combining equations 5.6 and 5.9 it is possible to express equation 5.8 as
follows:
E
Emaximal
=
[Rtot][L]
KdKE + ([Rtot] + KE)([L])
(5.10)
Equation 5.10 can be simplified by defining the transducer ratio τ , τ = [Rtot]
KE
:
E =
(Emaximal)(τ)([L])
Kd + ([L])(τ + 1)
=
([L])(Emaximal)(
τ
τ+1
)
Kd
τ+1
+ [L]
(5.11)
By using equation 5.11 it is possible to determine two factors about the
interaction of agonist and receptor namely:
• Potency - Defined as the ability of the ligand to bind the receptor
• Efficacy - The effect that the ligand bound receptor has on the trans-
activation of sensitive genes
The operational model of agonism describes the ability of the ligand to bind
the receptor as well as the ability of the ligand bound receptor to initiate
the transcription of sensitive genes. By incorporating the function τ it is
possible to mathematically account for the observation that ligands have
different effects in various tissues without accounting for the mechanism of
action. Experimentally it is possible to determine the affinity of the ligand
by determining the Kd, whilst it is possible to determine the efficacy of the
ligand bound receptor complex using promoter reporter gene studies.
5.2 Tripartite and Bipartite models
It is now known that hormones can have different effects depending on the
tissue where they are found and which receptors they interact with. These
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effects cannot be explained only using the ligand and receptor concentration
and thus new models had to be developed which could explain these obser-
vations. A new model proposed by Katzenellenbogen [107] states that the
selectivity of steroids for nuclear hormones may be mediated by three distinct
mechanisms:
• Ligand based selectivity
• Receptor based selectivity
• Effector site based selectivity
Ligand based selectivity The effects that are seen in various tissues
can be described by differences in pharmaco-kinetics, or differential ligand
metabolism. It can thus be said that the same hormone may be present in
various tissues, however, the relative amounts of the hormone in the tissue
differ because of altered uptake or metabolism.
Receptor based selectivity The receptor based mechanism of selectivity
states that tissues respond differently to the same hormones because the tis-
sues contain different levels of receptors. These differences in receptor levels
may be due to concentration or ratios of receptors, subtypes, isoforms, splice
variants or that the receptor have different states of covalent modification
(eg. phosphorylation).
Effector site based selectivity It has been noted that under certain con-
ditions, even in the absence of ligand and receptor based selectivity, hormones
can have different effects in tissues. These differences can be explained by
the presence of co-factors and the role that these co-factors play in the trans-
activation of genes.
There are currently two types of models which describe the interaction of
ligands with their respective receptors and the transactivation of genes via
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the ligand bound receptor complex. These models are the bipartite and
tripartite models.
5.2.1 Pharmacology of bipartite and tripartite systems
Bipartite systems
The original model that was proposed to describe the interactions of ligands
with their receptors, and any further physiological responses, accounted for
the presence of ligand and receptor. This was an operational model and
has been refined by Black and Leff [188]. The operational model related the
affinity of the ligand to a receptor using the term potency, whilst the ability
of the ligand receptor complex to initiate transcription was described by the
term efficacy. In this model it was the ligand which controlled the ability of
the ligand receptor complex to initiate a response. As such the implications
of the bipartite model is that the ligand controlled the shape and function
of the receptor directly and thus it was possible to assign a unique potency
and efficacy to each ligand.
Tripartite systems
The tripartite model is composed of three components namely the ligand, re-
ceptor and effector (co-regulators). It has been proposed that the tripartite
model describes steroid hormone pharmacology more accurately in that the
ligand binding and the response initiation functions are assigned to separate
functions: ligand binding to the receptor and response initiation to the ef-
fector.
The tripartite model differs to the bipartite model in a number of ways
which include the definition of potency and efficacy. The tripartite model
states that the ligand binding to the receptor forms a complex, and that
the affinity of this binding is the determining factor in ligand potency. The
ligand receptor interaction does not, however, control the response and is
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therefore not a direct determinant of ligand efficacy. The interactions of the
ligand receptor complex with the effector is the determining factor of the
efficacy of the ligand receptor complex. These effectors are commonly part
of the co-factor family and can thus be either co-activators or co-repressors.
Using the tripartite model it is possible to explain why the same ligand
may have different effects in various tissues, when interacting with the same
receptor. The reason for these differing effects may be that each tissue type
has it’s own milieu of effectors; such as co-factors, DNA sequences flanking
the response element, consensus and non-consensus response element; which
the tripartite model accounts for.
5.3 The physiologically based pharmacologi-
cal model
The physiologically based pharmaco-kinetic model was developed by Plowchalk
[190]. The aim of this model was to provide a quantitative tool with which to
evaluate the importance of physiological parameters on E2 blood and tissue
concentrations in rats and humans.
Estradiol is found in plasma in two forms, those being bound and unbound.
In humans both SHBG and albumin can bind estradiol and in so doing re-
strict the free fraction of estradiol in plasma. It is presumed that the free form
of estradiol is pharmacologically active, and is capable of passing through the
lipid bilayer and equilibrating with tissues. However, it has also been found
that under specific conditions, protein bound E2, is also available to tissue
uptake [1, 191].
In recent years interest has been expressed in using estradiol as a prototypi-
cal endocrine-active compound. Endocrine active compounds are a group of
chemicals that have been found to have an effect on the endocrine system,
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some of which are mediated via the estrogen receptor. The effects of these
endocrine active compounds are normally compared to those of estradiol in
the same system. The external dose of these compounds cannot be used as
the pharmacologically active concentration. The tissue concentration and the
potency of these compounds are determined by a number of factors which in-
clude binding affinity to ER-α and plasma binding proteins, ligand-receptor
competition, metabolic and total clearance rates and finally tissue and blood
partition coefficients. The physiologically based model attempts to take all
of these factors into account to determine which specific factors play a role
in the function of estrogenic compounds in the human physiological system.
In setting up the model number of assumptions were made: 1) ER-α concen-
tration in tissues were time and treatment independent, 2) Estrogen recep-
tors existed as a single subtype, 3) Type II estrogen estrogen binding sites
[192] were not taken into account, 4) The cytoplasm and nuclear ER-α were
both equally available in tissue. With respect to the disassociation constants
a Kd (E2) of 0.25nM was used for ER-α, consistent with literature values
of between 0.1 and 0.5nM [193, 194]. The Kd (E2) for SHBG was defined
as 1.5nM [158] and the Bmax was 19.36-38nM (males), 37-70nM (females),
400nm (pregnant females) [158]. The binding constants for albumin were
Kd (E2) = 1.7×104nM and Bmax = 5×105nM [158]. The metabolic clearance
of E2 was attributed solely to metabolism, which was assumed to take place
in the liver and central plasma compartment. It was also assumed that there
was no endogenous production of E2 either through de novo synthesis or re-
generation from conjugates.
The results of the modelling for E2 binding and fractional distribution be-
tween SHBG and albumin predicted that albumin would bind most of the
E2 in males and females, Table 5.1.
These results are in concurrence with the literature where it was shown that
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only a small percentage of E2 would be free in plasma [158]. The results of
the hepatic extraction for E2 were not similar to those found in the litera-
ture. It was concluded that the values were greater than would be expected
for the uptake of unbound E2 alone. Padridge [195] has demonstrated that
the in vitro binding constants for E2 are not predictive of in vivo binding
constants in the liver, brain and uterus. As a result of these findings it has
been proposed that an apparent Kd for a single organ would better reflect the
bio-available E2 fraction in plasma. With respect to the metabolic clearance
of E2 it was found that the hepatic blood flow was one of the most important
factors in experimental variability. The E2 concentration in plasma under
equilibrium conditions showed that only the infusion and clearance rates had
an influence, while other parameters such as partition coefficients, receptor
binding, blood flow, diffusional clearance rates and organ volumes only had
an impact on the time it took to reach a equilibrium state.
The following chapter will deal with the modelling of the Hep89 and human
pregnancy plasma experimental systems. As it is not possible to determine
the equilibrium concentration of all the binding proteins and their respec-
tive bound forms respectively, a numerical approach is used to calculate the
equilibrium concentrations.
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Table 5.1: Simulation results of predicted estradiol distribution in
plasma containing various protein compositions [190].
Free
(%)
Total
bound
(%)
Albumin
bound (%)
SHBG
bound (%)
Protein free plasma 100 0 0 0
Plasma with albumin
and SHBG (male)
2.5 97.5 73.8 23.7
Plasma with albumin
and SHBG (female)
1.9 98 58.3 39.7
Plasma with albumin
and SHBG (pregnant)
0.4 99.6 10.6 89
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Chapter 6
The influence of SHBG on E2
binding by ER-α: An in silico
approach
As was stated in the Chapter ?? the aim of this project was to build a
mathematical model that would describe the effect that SHBG has on the
binding of E2 to ER-α and thus influence SHBG has on this interaction.
As the results have shown there was difficulty when determining the binding
constants Bmax app and Kd app (E2) for ER-α in the presence of SHBG, however,
it was possible to determine the Bmax and Kd (E2) for ER-α in the absence
of SHBG. With respect to determining the Kd (E2) for SHBG it was shown
that this coild not be achieved. As a result of these setbacks the proposed
mathematical model, was not built, and instead models that describe the
experimental systems, those being the Hep89 and human pregnancy plasma,
were built. These model are being built in an attempt to determine why the
binding constants for ER-α and SHBG were not determined in these systems.
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6.1 Model of the Hep89 experimental system
The aim of modelling the Hep89 experimental system was to provide an ex-
planation as to why it was not possible to determine the binding constants
for ER-α, Kd app (E2) and Bmax app. An example of the experimental system
is shown in Figure 6.1. It should be noted that neither SHBG nor albu-
min were included in the extracellular compartment. This is in keeping with
the experimental system where the medium was removed before the binding
studies were performed. The presence of albumin has been included because
the Hep89 cells were derived from a liver hepatacoma and thus should con-
tain albumin.
Medium
E2
SHBG
SHBG.E2
Albumin
Albumin.E2
ER
ER.E2
E2
Cytoplasm
Figure 6.1: Diagram of the Hep89 experimental system. This system
describes the binding of E2 to ER-α in the presence of intracellular albumin and
SHBG.
The variables that are needed to build this model are shown in Table 6.1. As
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there is no information on the amount of ER-α expressed in Hep89 cells it
was decided to use the Bmax values that were determined in the COS-1 cells
system. These values were used because both these cell lines were transfected
with the same plasmid containing the ER-α gene.
The amount of cytostolic SHBG was calculated by using the ratio of in-
tracellular SHBG to extracellular SHBG (shown as pg/µg DNA [142]) and
then using this ratio to calculate the cytostolic SHBG from the extracellular
SHBG concentration (20nM) as reported by Brown-Martin et al [137].
The concentration of albumin in Hep89 cells was estimated on the basis
of the amount that is normally present in plasma and applying the same
ratio that was used to determine the cytostolic concentration of SHBG. This
was done as there is no literature reporting on the concentration of albumin
in Hep89 cells.
The mathematical model was consisted of two compartments, the cytoplasm
and nucleus were treated as one compartment (cytostolic) while the extra-
cellular medium was treated as a separate compartment (medium). The
transfer of E2 across the membrane was governed by mass action kinetics as
was the binding of E2 to the binding proteins (ER-α, SHBG and albumin).
The role that the Kd (E2) for ER-α had on the binding kinetics was studied
by varying the Kd (E2) between 0.25nM and 4.4nM, Table 6.1.
The following chemical equilibria were used to describe the binding of E2
to binding proteins and the transfer of E2 across the membrane.
E2medium 
 E2cytosol
ER-αcytosol + E2cytosol 
 ER-αcytosol.E2cytosol
SHBGcytosol + E2cytosol 
 SHBGcytosol.E2cytosol
albumincytosol + E2cytosol 
 albumincytosol.E2cytosol
(6.1)
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Table 6.1: Values that were used to initialize the Hep89 model.
Bmax nM Reference
ER-α 1.2 experimental (section 4.1.1)
SHBG 0.63 - 0.98 calculated from [142] and [137]
albumin 1.9×104 estimated using ratio determined for
SHBG concentration
Kd (E2) nM Reference
ER-α 0.25 [190]
3.4 experimental (section 4.1.1)
4.4 experimental (section 4.1.1)
SHBG 1.5 [158]
albumin 1.9×104
E2 transfer 1 in silico
Volumes (L) Reference
Medium 0.001 experimental (section 4.5)
Cytosol 5.96×10−6 experimental (section 4.5)
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As it is not possible to analytically solve all of the above equations simul-
taneously so as to calculate the equilibrium concentration of all the species
involved it was decided to use numerical modelling to solve these equilib-
ria. The numerical modelling of this system was accomplished using Gepasi
[196]. The initial concentration of E2 medium was varied between 1×10−13 nM
and 30nM and the equilibrium concentrations of the various species 6.1 was
calculated.
Initially only ER-α was included so as to determine the Kd (E2) in the ab-
sence of SHBG and albumin. The results obtained, that is the concentration
of E2 bound ER-α, was fitted to a one site binding equation 6.2. The one
site binding equation was used to calculate the Kd app and Bmax app for ER-α
binding E2 in the presence of SHBG and albumin.
[ER-α.E2] =
[ER-αtot].[E2 cytosol]eq
Kd + [E2cytosol]eq
(6.2)
The following discussion will concentrate on the binding of E2 to ER-α and
the results obtained when a one site binding, equation 6.2, was fitted to the
equilibrium concentrations of ER-αcytosol.E2cytosol in the presence or absence
of SHBG and albumin.
With respect to the binding of E2 to ER-α in the absence of SHBG and
albumin it was noted that the dilution of E2, by the cytoplasmic compart-
ment, did not influence the Kd (E2). This was noticed when comparing the
Kd as published by Plowchalk [190] which was determined as 0.25nM, to
that obtained via modelling 0.25nM, Figure 6.2. In general it was noted
that when the Kd (E2) for ER-α was increased the equilibrium concentration
of E2 bound ER-α decreased. The decrease in equilibrium concentration of
E2 bound ER-α can be seen when the Kd (E2) was increased from 0.25nM to
3.4nM and 4.4nM , Table 6.2 and Figure 6.2. This is to be expected as when
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the Kd (E2) is lowered ER-α has a lower affinity for E2 and thus equilibrium
will only be reached at higher concentrations of E2.
2]e
q (
nM
)
[3H−E2] nM
[E
R_
E
Kd = 4.4nM
 0.2
 0.4
 0.6
 0.8
 1
 1.2
 1.4
 1.6
 0  5  10  15  20  25  30
Kd = 0.25nM
Kd = 3.4nM
 0
Figure 6.2: The influence that the Kd app (E2) has on the binding of E2
to ER-α in the absence of SHBG and albumin. The equilibrium
concentration of E2 bound ER-α was determined for a system where E2 can cross
a membrane and bind to ER-α. The Kd (E2) for ER-α was varied between 0.25,
3.4 and 4.4nM.
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When determining the influence that SHBG has on the binding of E2 it
was noted that there was an apparent increase, though very little, in the
Kd (E2) (Kd app (E2)), Table 6.2. In the presence of 0.63nM SHBG the Kd (E2),
defined as 0.2500nM was increased from 0.2500nM to 0.2551nM, while in the
presence of 0.98nM of SHBG increased the Kd app (E2) to 0.2553, Table 6.2.
The same trend was noticed when the Kd (E2) was defined as 3.4nm or 4.4nM
Table 6.2. The apparent maximal binding stayed the same in the presence
of 0.63nM SHBG and 0.98nM of SHBG 6.2. From these results, Figure 6.3
it was shown that the right shift in the Kd app because of the presence of
SHBG affecting the equilibrium concentrations of free E2 Table 6.3. In the
absence of SHBG at least 94% of E2 was unbound while in the presence of
0.98nM SHBG the amount of unbound E2 was decreased to 93.35%. The
results pertaining to SHBG would thus seem to indicate that SHBG binds
E2, which effects the levels of unbound E2. This decrease in the levels of
unbound E2 in turn affects the Kd app (E2) for E2 binding ER-α.
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Figure 6.3: The influence that SHBG has on the binding of E2 to
ER-α. SHBG concentrations were varied between 0.63nM and 0.98nM. The use
of various Kd (E2) values (0.25nM) was also studied. The equilibrium
concentration of ER-α bound E2 was numerically determined using Gepasi when
the concentration of E2 was varied between 1×10−13 nM and 30 nM. (a) Kd (E2)
for ER-α = 0.25nM, (b) Kd (E2) for ER-α = 0.25nM, [SHBG] = 0.63nM,(c)
Kd (E2) for ER-α = 0.25nM, [SHBG] = 0.98nM.
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The influence that albumin has on the binding of E2 to ER-α can be seen
when determining the Kd app (E2) and apparent maximal binding, Table 6.2.
In the presence of both albumin and SHBG it can be seen that the Kd app (E2)
(0.2569nM), is increased from 0.2553nM in the presence of 0.98nM SHBG,
and 0.2547nM in the presence of ER-α alone, if the Kd (E2) was initially
defined as 0.25nM. Once again it was noted that the maximal binding cal-
culated at equilibrium was not affected, Table 6.2. The apparent shift in Kd
is once again related to the lower concentrations of E2 that are available at
equilibrium, Figure 6.4 and Table 6.4. The influence of SHBG and albumin
together to limit the binding of E2 to ER-α, as well as the influence that the
Kd (E2) for ER-α can be seen in Figure 6.5.
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Figure 6.4: The influence that SHBG and albumin have on the
binding of E2 to ER-α. SHBG concentrations were varied between 0.63nM
and 0.98nM while the concentration of albumin was 1.9×104 nM. The use of
various Kd (E2) values (0.25nM) was also studied. The equilibrium concentration
of ER-α bound E2 was numerically determined using Gepasi when the
concentration of E2 was varied between 1×10−13 nM and 30 nM. (a) Kd (E2) for
ER-α = 0.25nM, (b) Kd (E2) for ER-α = 0.25nM, [SHBG] = 0.63nM, (c) Kd (E2)
for ER-α = 0.25nM, [SHBG] = 0.98nM.
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Table 6.2: Results of numerical modelling for Hep89 cells.
Binding proteins Concentration (nM) Kd app Bmax app
(ER-α only nM)
Kd (E2) = 0.25nM
ER-α 1.20 0.25 1.20
SHBG 0.67 0.25 1.20
0.98 0.25 1.20
SHBG and albumin 0.67 1.9×104 0.25 1.20
0.98 1.9×104 0.25 1.20
Kd (E2) = 3.4nM
ER-α 1.20 3.42 1.20
SHBG 0.67 3.43 1.20
0.98 3.42 1.20
SHBG and albumin 0.67 1.9×104 3.44 1.20
0.98 1.9×104 3.45 1.20
Kd (E2) = 4.4nM
ER-α 1.20 4.42 1.20
SHBG 0.67 4.43 1.20
0.98 4.43 1.20
SHBG and albumin 0.67 1.9×104 4.45 1.20
0.98 1.9×104 4.46 1.20
The concentration of E2 was 30nM in the presence or absence of SHBG
and albumin. The equilibrium concentration of ER-α bound E2 (ER-α.E2)
was calculated and fitted to a one site binding equation.
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Table 6.3: Results for the distribution of E2 between the binding
proteins in the Hep89 experimental system, expressed as a percentage.
Binding Concentration % E2 % E2 % E2 %E2
proteins (nM) unbound bound to bound to bound to
ER-α SHBG albumin
Kd (E2) = 0.25nM
None 100.00 0.00 0.00 0.00
ER-α 1.20 96.16 3.83 0.00 0.00
SHBG 0.67 94.22 3.76 2.02 0.00
0.98 93.35 3.73 2.92 0.00
SHBG and albumin 0.67 1.9×104 45.93 1.85 0.99 51.24
0.98 1.9×104 45.72 1.84 1.44 51.01
Kd (E2) = 3.4nM
None 100.00 0.00 0.00 0.00
ER-α 1.20 96.51 3.49 0.00 0.00
SHBG 0.67 94.59 3.42 2.02 0.00
0.98 93.68 3.38 2.93 0.00
SHBG and albumin 0.67 1.9×104 46.02 1.67 0.99 51.33
0.98 1.9×104 45.81 1.66 1.44 51.10
Kd (E2) = 4.4nM
None 100.00 0.00 0.00 0.00
ER-α 1.20 96.63 3.39 0.00 0.00
SHBG 0.67 94.68 3.32 2.03 0.00
0.98 93.81 3.29 2.94 0.00
SHBG and albumin 0.67 1.9×104 46.04 1.62 0.99 51.35
0.98 1.9×104 45.83 1.62 1.44 51.12
The concentration of E2 was 30nM in the presence or absence of SHBG and
albumin. The percentages of E2 bound to each protein was calculated as
the concentration of E2 bound protein over total internal E2 concentration
and then expressed as a percentage.
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Table 6.4: Results for the distribution of E2 between the binding
proteins in the Hep89 experimental system.
Binding Concentration [E2] nM [E2] nM [E2] nM [E2] nM [E2] nM
proteins (nM) Total unbound bound to bound to bound to
ER-α SHBG albumin
Kd (E2) = 0.25nM
ER-α 1.20 31.01 29.82 1.19
SHBG 0.67 31.64 29.81 1.19 0.64
0.98 31.93 29.81 1.19 0.93
SHBG and albumin 0.67 1.9×104 64.49 29.62 1.19 0.64 33.04
0.98 1.9×104 64.78 29.61 1.19 0.93 33.04
Kd (E2) = 3.4nM
ER-α 1.20 30.89 29.82 1.08
SHBG 0.67 31.53 29.81 1.08 0.64
0.98 31.82 29.81 1.08 0.93
SHBG and albumin 0.67 1.9×104 64.37 29.62 1.08 0.64 33.04
0.98 1.9×104 64.67 29.62 1.08 0.93 33.04
Kd (E2) = 4.4nM
ER-α 1.20 30.86 29.82 1.05
SHBG 0.67 31.50 29.81 1.05 0.64
0.98 31.79 29.81 1.05 0.93
SHBG and albumin 0.67 1.9×104 64.34 29.62 1.05 0.64 33.04
0.98 1.9×104 64.63 29.62 1.05 0.93 33.04
The concentration of E2 was 30nM in the presence or absence of SHBG
and albumin. The amount of E2 bound to each protein was calculated
mathematically with the aid of Gepasi. The data represented in this table
shows the absolute concentration (nM) of E2 bound to each protein.
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Figure 6.5: The influence that SHBG and albumin have on the
binding of E2 to ER-α. SHBG concentrations were varied between 0.63nM
and 0.98nM while the concentration of albumin was 1.9×104 nM. The use of
various Kd (E2) values (0.25nM and 4.4nM) was also studied. The equilibrium
concentration of ER-alpha bound E2 was numerically determined using Gepasi
when the concentration of E2 was varied between 1×10−13 nM and 30 nM. (a)
and (f) are ER-α only, Kd (E2) = 0.25 and 4.4nM respectively. (a) through (e) Kd
= 0.25nM, (f) through (j) Kd (E2) = 4.4nM. (b,c,g,h) [SHBG] = 0.63nM. (e,f,i,j)
[SHBG] = 0.98nM. (c,e,h,j) [albumin] = 1.9×104 nM.
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The following discussion will center around the results that could be ex-
pected in an experimental situation. For the purposes of this discussion the
maximal binding in the presence of SHBG is calculated as the sum of the
ER-α and SHBG bound E2. In the presence of SHBG and albumin the same
principle is applied. Maximal binding is calculated using this principle be-
cause in an experimental situation it would not be possible to distinguish
the ER-α bound E2 from either SHBG or albumin bound E2, in this specific
experimental system.
The results of the modelling of saturation binding experiments using Hep89
cells showed that it was not possible to reach saturating conditions if SHBG
and albumin were both present 6.7 and 30nM of E2 was used. In the presence
of only ER-α and SHBG it is possible to reach saturating conditions, Figure
6.6. The only difference between the absence of SHBG and presence of SHBG
the maximal binding in higher is in the presence of SHBG. There is also a
slight right shift of the Kd app (E2) as has already been shown. When both
albumin and SHBG are present it can be seen that saturating conditions are
not reached, Figure 6.7. Using this information it should be possible to see
that the presence of albumin is interfering with the binding of E2 to ER-α
and that saturating conditions are not met.
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Figure 6.6: The influence of SHBG on the binding of E2 to ER-α. The
concentration of ER-α used was 1.2nM, SHBG concentration was set as 0.98nM.
The Kd for E2 binding ER-α was set as 0.25nM. The equilibrium concentration
of ER-α and SHBG bound E2 was numerically determined using Gepasi when
the concentration of E2 was varied between 1×10−13 nM and 30nM. Maximal
binding was calculated as the sum of E2 bound ER-α and SHBG, in the presence
of SHBG. In the absence of SHBG maximal binding was defined as the
equilibrium concentration of E2 bound ER-α.
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Figure 6.7: The influence of SHBG and albumin on the binding of E2
to ER-α. The concentration of ER-α used was 1.2nM, SHBG concentration was
set as 0.98nM while the concentration of albumin was 1.74×104 nM. The Kd for
E2 binding ER-α was set as 0.25nM. The equilibrium concentration of ER-α,
SHBG and albumin bound E2 was numerically determined using Gepasi when
the concentration of E2 was varied between 1×10−13 nM and 30nM. Maximal
binding was calculated as the sum of E2 bound ER-α and SHBG, in the presence
of SHBG and as the sum of ER-α, SHBG and albumin bound E2, in the presence
of SHBG and albumin. In the absence of SHBG or albumin maximal binding was
defined as the concentration of E2 bound ER-α at equilibrium.
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6.2 Model of human plasma experimental sys-
tem
The aim of modelling the binding of E2 in human pregnancy plasma was to
determine why saturating conditions were not reached. To explain these re-
sults the experimental system of Hammond [180] will be modelled after which
the experimental system as was used in this study will be modelled. Both of
these systems were being modelled to highlight the differences between the
experimental systems, so as to give an explanation as to why saturating con-
ditions were not reached in the experiments performed in human pregnancy
plasma.
6.2.1 Binding of dihydrotestosterone to SHBG in hu-
man pregnancy plasma
An experimental system to determine the binding constants, Kd and Bmax,
for SHBG binding dihydrotestosterone (DHT) was proposed by Hammond
[180]. The presence of albumin was not explicitly mentioned by Hammond
although it is known that albumin is present in human pregnancy plasma
[158], and as such albumin has been included in this model.
The experimental approach used by Hammond relied on SHBG and CBG
both binding DHT and cortisol. As CBG binds cortisol with a higher affinity
than SHBG, cortisol was included to counteract the effect that CBG binding
DHT would have on SHBG binding DHT. The Specific binding of DHT to
SHBG was calculated from the Total binding of DHT minus the non specific
binding of DHT. Total binding was determined as the binding of 3H-DHT in
the presence of 66.67 nM of cortisol. Non Specific binding was determined
as the binding of 3H-DHT in the presence of 1666.67 nM DHT and 66.67 nM
cortisol.
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SHBG.DHT
DHT
SHBGalbuminCBG
CBG.cortisol albumin.cortisol SHBG.cortisol
cortisol
CBG albumin SHBG
CBG.DHT albumin.DHT
Figure 6.8: Experimental system that was used by Hammond [180].
The experimental system used by Hammond when binding dihydrotestosterone
(DHT) and cortisol to SHBG and corticosteroid binding protein (CBG) in the
presence of albumin.
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The chemical equilibria used to describe the experimental system are as fol-
lows for Total binding:
SHBG +DHTlabelled 
 SHBG.DHTlabelled
CBG+DHTlabelled 
 CBG.DHTlabelled
albumin + DHTlabelled 
 albumin.DHTlabelled
SHBG + cortisol
 SHBG.cortisol
CBG + cortisol
 CBG.cortisol
albumin + cortisol
 albumin.cortisol
(6.3)
where DHTlabelled is
3H-DHT.
and for Non Specific binding:
SHBG +DHTlabelled 
 SHBG.DHTlabelled
CBG+DHTlabelled 
 CBG.DHTlabelled
albumin + DHTlabelled 
 albumin.DHTlabelled
SHBG + cortisol
 SHBG.cortisol
CBG + cortisol
 CBG.cortisol
albumin + cortisol
 albumin.cortisol
SHBG +DHT
 SHBG.DHT
CBG+DHT
 CBG.DHT
albumin + DHT
 albumin.DHT
(6.4)
The kinetic binding constants for all of the interactions are shown in Table
6.5 as are the values that were used to initialize the model.
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Table 6.5: Kinetic constants for SHBG, CBG and albumin.
Protein Steroid Kd (nM)
SHBG DHT 0.18
cortisol 625
CBG DHT 1204.82
cortisol 13.16
albumin DHT 4×104
cortisol 3×103
Protein Concentration (nM)
Concentration (nM) 200x dilution 100x dilution
SHBG 0.67 1.33
CBG 1.77 3.53
albumin 833.33 1587.30
Steroid Concentration (nM)
3H-DHT 0.33 - 16.67
DHT 1666.67
cortisol 66.7
The values that were used to initialize the model, these include bind-
ing constants (Bmax and Kd) as well as protein and steroid concen-
trations.
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As it is not possible to analytically determine the equilibrium concentra-
tion of all the species mentioned numerical modelling, with the aid of Gepasi,
was used. The amount of 3H-DHT was varied between 1×10−13 nM and 16.67
nM, and the equilibrium concentrations of the various species calculated.
The binding curves for Total binding, Non Specific binding and Specific bind-
ing are shown in Figure 6.9, for plasma diluted 200 times, and Figure 6.10,
for plasma diluted 100 times. Total binding was calculated as the amount
of SHBG, albumin and CBG bound 3H-DHT while non specific binding was
calculated as the amount of albumin and CBG bound 3H-DHT in the pres-
ence of 1666.67 nM DHT. From these results it was shown that when plasma
was diluted 200 and 100 times saturating conditions were reached. These
results are in concordance with those of Hammonds [180].
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Figure 6.9: Modelling results for the binding of DHT in plasma diluted
200 times. The binding of DHT to SHBG, CBG and albumin in plasma that
was diluted 200 times was modelled. The concentration of protein bound by
3H-DHT under total, non specific and specific binding conditions was calculated
with the aid of Gepasi. The Specific binding was calculated as the binding of
3H-DHT in the presence of 66.67 nM cortisol and absence of DHT minus the
binding of 3H-DHT in the presence of 1666.67 nM DHT and 66.67 nM cortisol at
equilibrium. Maximal binding was calculated as the sum of SHBG, albumin and
CBG bound 3H-DHT, at equilibrium, for any given concentration of 3H-DHT.
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Figure 6.10: Modelling results for the binding of DHT in plasma
diluted 100 times. The binding of DHT to SHBG, CBG and albumin in plasma
that was diluted 100 times was modelled. The concentration of protein bound by
3H-DHT under total, non specific and specific binding conditions was calculated
with the aid of Gepasi. The Specific binding was calculated as the binding of
3H-DHT in the presence of 66.67 nM cortisol and absence of DHT minus the
binding of 3H-DHT in the presence of 1666.67 nM DHT and 66.67 nM cortisol at
equilibrium. Maximal binding was calculated as the sum of SHBG, albumin and
CBG bound 3H-DHT, at equilibrium, for any given concentration of 3H-DHT.
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To explain these results the percentage of free ligand as well as the per-
centage bound to SHBG, CBG and albumin was calculated. The percentage
bound was calculated as the ratio between the concentration of bound pro-
tein to the total amount of the steroid present initially. This ratio was then
converted to a percent of 100, Table 6.6.
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Table 6.6: Results for the distribution of 3H-DHT between the
binding proteins, expressed as a percentage.
Total (nM) % Free % bound to % bound to % bound to
SHBG albumin CBG
Total binding, 200x dilution of plasma
3H-DHT 16.67 94.19 3.97 1.84 0.02
cortisol 66.67 77.70 0.1 20.20 2.11
Non Specific binding, 200x dilution of plasma
3H-DHT 16.67 98.12 0.04 1.84 0.02
DHT 1666.67 98.10 0.04 1.84 0.02
cortisol 66.67 78.68 0.1 19.65 1.66
Total binding, 100x dilution of plasma
3H-DHT 16.67 88.61 7.88 3.47 0.06
cortisol 66.67 63.08 0.1 32.90 4.02
Non Specific binding, 100x dilution of plasma
3H-DHT 16.67 96.27 0.08 3.62 0.05
DHT 1666.67 96.25 0.08 3.62 0.05
cortisol 66.67 64.54 ¡0.1 32.37 3.08
The concentration of 3H-DHT was varied between 1×10−13 nM and 16.67
nM in the presence of SHBG, CBG and albumin. The percentages of
3H-DHT bound to each protein was calculated as the concentration of
3H-DHT bound protein over Total 3H-DHT concentration (16.67 nM) and
then expressed as a percentage.
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Table 6.7: Results for the distribution of the binding proteins (SHBG,
albumin and CBG) expressed as a percantage.
Total (nM) % Free % bound to % bound to % bound to
3H-DHT DHT cortisol
Total binding, 200× dilution of plasma
SHBG 0.67 1.13 98.77 0.09
albumin 833.33 98.35 0.04 1.61
CBG 1.77 20.21 0.26 79.53
Non specific binding, 200× dilution of plasma
SHBG 0.67 0.01 0.99 99.00 0.0009
albumin 833.33 94.71 0.04 3.68 1.57
CBG 1.77 15.73 0.21 21.34 62.70
Total binding, 100× dilution of plasma
SHBG 1.33 1.20 98.71 0.08
albumin 1587.30 98.58 0.04 1.38
CBG 3.53 99.71 0.29 75.94
Non specific binding, 100× dilution of plasma
SHBG 1.33 0.01 0.99 99.00 0.0007
albumin 1587.30 94.80 0.04 3.80 1.35
CBG 3.53 17.81 0.23 23.71 58.23
The concentration of 3H-DHT was varied between 1×10−13 nM and 16.67
nM in the presence of SHBG, CBG and albumin. The concentration of
DHT, 3H-DHT and cortisol bound binding proteins (SHBG, albumin and
CBG) was calculated and expressed as a percentage.
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From the results of these calculations it can be seen that the relative
distribution of 3H-DHT changes when comparing the plasma diluted 200,
Figure 6.9, times and 100 times, Figure 6.10. In the plasma that was diluted
100 times it can be seen that there is ligand depletion in that more than
10% of 3H-DHT is bound, Table 6.6. With respect to the use of cortisol in
the assay it was found that this prevented the binding of 3H-DHT to CBG
to an extent and in the absence the amount of specific binding is increased
minimally, Table 6.7. These results would suggest that it is not the relative
distribution of 3H-DHT that is the cause for non saturating conditions being
reached in plasma that was diluted 100 times. The results of the modelling
has shown that when plasma was diluted 100 times the amount of ligand
that was bound was more than 10%, and as there is more than one binding
protein it is difficult to calculate the binding constants (Bmax and Kd (DHT) for
SHBG). This may have been the reason why it was not possible to determine
the binding constants for SHBG using human pregnancy plasma that was
diluted 100 times, as stated by Hammond [180].
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6.2.2 Binding of E2 to SHBG in human pregnancy
plasma
The aim of the following section of work is to determine why when saturation
binding assays were performed, using human pregnancy plasma, saturating
conditions were not reached. The experimental approach was similar to that
of Hammond [180] except for the following conditions:
• Saturation binding experiments were performed using 3H-E2 to deter-
mine the Kd (E2) for SHBG binding E2.
• Human pregnancy plasma was only diluted 25 times
• No cortisol was used to prevent the binding of E2 to CBG as CBG has
no affinity for E2 [158].
To determine whether diluting the plasma 200 times has on the final out-
come, the model will include a description of conditions that would have been
encountered if the plasma was diluted 200 times.
A graphical description of the experimental system can be seen in Figure
6.11. From this diagram it can be seen that E2 can bind either SHBG or
albumin. The binding of 3H-E2 to SHBG in the absence in the absence of
an excess of E2 was used to determine the Total binding. Non specific bind-
ing was performed under the same circumstances except that and excess,
1×104nM E2, was added. Specific binding was calculated as Total binding -
non specific binding.
The chemical equilibria that describe this experimental system are shown
in equations 6.5 and 6.6. The chemical equilibria that describe Total binding
are as follows:
SHBG + 3H-E2 
 SHBG.3H-E2
albumin + 3H-E2 
 albumin.3H-E2 (6.5)
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SHBG.E2
E2
SHBG
albumin.E2
albumin
Figure 6.11: Experimental system that was used in saturation binding
assays in human pregnancy plasma using E2. The diagram shows the
binding of E2 to SHBG and albumin as would have been the case in human
pregnancy plasma.
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The chemical equilibria that describe Non Specific binding are as follows:
SHBG + 3H-E2 
 SHBG.3H-E2
SHBG + E2 
 SHBG.E2
albumin + 3H-E2 
 albumin.3H-E2
albumin + E2 
 albumin.E2 (6.6)
The kinetic binding constants for all of the interactions are shown in Table
6.8 as are the values that were used to initialize the model.
Table 6.8: Kinetic constants for SHBG and albumin.
Protein Steroid Kd (nM)
SHBG E2 1.5
albumin E2 1.7×104
Protein Concentration (nM)
200x dilution 25x dilution
SHBG 0.67 5.33
albumin 833.33 6349.21
Steroid Concentration (nM)
3H-E2 1×10−13 - 30
E2 1×104
The values that were used to initialize the model, these include bind-
ing constants (Bmax and Kd) as well as protein and steroid concen-
trations.
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As it is not possible to analytically determine the equilibrium concentra-
tion of all the species mentioned numerical modelling, with the aid of Gepasi,
was used. The amount of 3H-E2 was varied between 1×10−13 nM and 30nM,
and the equilibrium concentrations of the various species calculated.
The binding curves for Total binding, Non Specific binding and Specific bind-
ing are shown in Figure 6.12, for plasma diluted 25 times, and Figure 6.13,
for plasma diluted 200 times. Total binding was calculated as the amount of
SHBG and albumin 3H-E2 while non specific binding was calculated as the
amount of albumin bound 3H-E2 in the presence of 1×104nM E2.
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Figure 6.12: Modelling results for the binding of E2 in plasma diluted
25 times. The binding of E2 to SHBG and albumin in plasma that was diluted
25 times was modelled. The concentration of protein bound by 3H-E2 under
total, non specific and specific binding conditions was calculated via the aid of
Gepasi. The Specific binding was calculated as the binding of 3H-E2 and absence
of E2 minus the binding of 3H-E2 in the presence of 1×104 nM E2 at equilibrium.
Maximal binding is defined as the amount of protein (the sum of SHBG and
albumin) bound by 3H-E2, at equilibrium, for any given concentration of 3H-E2.
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Figure 6.13: Modelling results for the binding of E2 in plasma diluted
200 times. The binding of E2 to SHBG and albumin in plasma that was diluted
200 times was modelled. The concentration of protein bound by 3H-E2 under
total, non specific and specific binding conditions was calculated via the aid of
Gepasi. The Specific binding was calculated as the binding of 3H-E2 and absence
of E2 minus the binding of 3H-E2 in the presence of 1×104 nM E2 at equilibrium.
Maximal binding is defined as the amount of protein (the sum of SHBG and
albumin) bound by 3H-E2, at equilibrium, for any given concentration of 3H-E2.
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For the purposes of this discussion maximal binding was calculated as
the concentration of SHBG.3H-E2. From the results of these models it was
concluded that when human pregnancy plasma was diluted 25 times it was
not possible to reach saturating conditions, as can be seen when Specific
binding was plotted 6.12. When examining the results for human pregnancy
plasma diluted 200 times it was noted that when Specific binding was plotted,
saturating conditions were also not reached 6.13. To explain these results
the percentage of free ligand as well as the percentage bound to SHBG and
albumin was calculated. The percentage bound was calculated as the ratio
between the concentration of bound protein to the total amount of the steroid
present initially. This ratio was then converted to a percent of 100, Table
6.9.
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Table 6.9: Results for the distribution of E2 between the binding
proteins, expressed as a percentage.
Total (nM) % Free % bound to % bound to
SHBG albumin
Total binding, 200x dilution of plasma
3H-E2 30.00 93.22 2.21 4.56
Non Specific binding, 200x dilution of plasma
3H-E2 30.00 97.11 0.01 2.88
E2 10000.00 97.11 0.01 2.88
Total binding, 25x dilution of plasma
3H-E2 30.00 60.87 16.42 22.71
Non Specific binding, 25x dilution of plasma
3H-E2 30.00 79.70 0.05 20.25
E2 10000.00 79.70 0.05 20.25
The concentration of 3H-E2 was varied between 1×10−13 nM and 30nM in
the presence of SHBG and albumin. The percentages of 3H-E2 bound to
each protein was calculated as the concentration of 3H-E2 bound protein
over Total 3H-E2 concentration (30nM) and then expressed as a percent-
age.
111
6.2 Model of human plasma experimental system
Table 6.10: Results for the distribution of bound and unbound binding
proteins, as expressed as a percentage.
Total (nM) % Free % bound to 3H-E2 % bound to E2
Total binding, 200× dilution of plasma
SHBG 0.67 0.84 99.16
albumin 833.33 99.84 0.16
Non specific binding, 200× dilution of plasma
SHBG 0.67 0.02 0.30 99.69
albumin 833.33 65.31 0.10 34.59
Total binding, 25× dilution of plasma
SHBG 5.33 7.59 92.41
albumin 6349.21 99.89 0.11
Non specific binding, 25× dilution of plasma
SHBG 5.33 0.02 0.30 99.68
albumin 6349.21 68.02 0.10 31.89
The concentration of 3H-E2 was varied between 1×10−13 nM and 30nM
in the presence of SHBG and albumin. The distribution of the binding
proteins between 3H-E2 and E2 was calculated and expressed as a per-
centage.
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The results of determining the amount of E2 bound to the SHBG or albu-
min showed that when human pregnancy plasma was diluted 200 times there
was less than 10% ligand depletion. When plasma was diluted 25 times it
was noted that there was about 40% ligand depletion. With respect to the
apparent right shift in the Kd, it should be noted as there is more SHBG
and albumin present in the plasma that was diluted 25 times, as compared
to 200 times, equilibrium binding would occur at higher concentrations of E2.
When examining the binding of 3H-E2 and E2 by the various binding proteins
it was noted that at least 99% of SHBG was bound by 3H-E2 whilst not much
albumin, about 0.3%, was bound by 3H-E2, Table 6.10. This is in keeping
with the Kd E2 for SHBG and albumin. When examining the binding of E2
to SHBG in the absence of albumin when human plasma is diluted 200 times
it is noted that it is possible to saturate SHBG, Figure 6.13.
From these results it was concluded that when human pregnancy plasma
was diluted 25 times it would not have been possible to saturate SHBG, as
was found experimentally. When examining the role of diluting plasma 200
times before performing saturation binding assays it was noted that the only
real differences would have been a increase in the Kd app (E2) and Bmax app.
It was also noted that when plasma was diluted 200 times and no albumin
was present it was possible to saturate SHBG using 30nM 3H-E2, Figure 6.13.
When comparing this experimental system to the one Hammond used it
should be noted that the Kd (DHT) for DHT binding SHBG, Kd is 0.18nM
is significantly lower than the affinity that SHBG has for E2, Kd is 1.5nM.
With respect to the presence of cortisol in Hammond’s experimental system
it was noted that both albumin and CBG bound cortisol. The binding of
cortisol by CBG and albumin would have decreased the Non Specific bind-
ing of 3H-DHT, and thus there would have been a higher concentration of
DHT available for binding to SHBG. In the experimental system described
113
6.2 Model of human plasma experimental system
in this system there was no cortisol present and thus there would have been a
higher amount of non specifically bound 3H-E2. In conclusion the modelling
of Hammond’s system and the experimental system used in this study has
highlighted the differences between the two systems. By comparing these sys-
tems it has been shown that when attempting to perform saturation binding
assays using E2, in human pregnancy plasma, the presence of albumin has a
negative influence.
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Chapter 7
Conclusion
The aim of this study was to determine to what extent SHBG modulates
the binding of E2 to ER-α and the subsequent transactivation of an ERE
reporter gene. The data obtained from these experiments was to be used
to build a mathematical model to describe these interactions. The following
discussion will deal with the conclusion of the experimental and modelling
results.
From the results of the binding studies in COS-1 cells it was possible to
determine that the Kd (E2) for ER-α was between 3.4 and 4.4nM. These val-
ues are in accordance with those reported by Pederson [179]. The results are
however not in accordance with those determined by Kuiper et al [49] who
determined the Kd (E2) as 0.5nM when using a pure solution of ER-α protein.
One of the factors that was shown to have an effect on the Kd, when working
in a whole cell system, was the transfer of E2 across the cell membrane as
shown in Chapter 6. As COS-1 cells were transiently transfected it is not
possible to discuss the relevance of the Bmax that was determined, as the
values determined cannot be compared to the physiological concentrations
of ER-α in humans.
The results of the saturation binding assays performed using Hep89 cells
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showed that when using 30nM of 3H-E2 saturation conditions were not
reached. As there is no literature available for saturation binding assays
performed in Hep89 cells a mathematical model was built to describe the
experimental system. The results of this model showed that the transfer of
E2 across the membrane caused a shift in the saturation binding curve. This
shift was as a result of a decrease in the maximal binding and an increase
in the Kd app (E2 . The reason for the decrease in maximal binding is under-
standable when one determines the equilibrium concentration of E2 in the
extracellular and intracellular compartment in the absence of binding pro-
teins. Initially 30nM of E2 was in the extracellular compartment, after the
transfer of E2 across the membrane and equilibrium had been reached there
is roughly 29nM of E2 in both the extracellular and intracellular compart-
ments. The apparent decrease in the maximal binding and Kd can thus be
explained by the decreased equilibrium concentration of E2 as compared to
the total amount of E2 that was initially present. With respect to the role
that SHBG had on the binding of E2 to ER-α it was found that even at the
highest concentration of SHBG, 0.98nM, it was still possible to saturate ER-
α. When albumin was introduced, as would be the case in the experimental
system, it was still possible to saturate ER-α but there was an increase in the
Kd app (E2). This was expected because albumin binds E2 and thus lowering
the equilibrium concentration of unbound E2. When the maximal binding
that would be expected in the case of an experimental system was calculated,
that is the sum of ER-α, SHBG and albumin bound E2, it was found that in
the presence of SHBG and albumin saturating conditions were not reached.
It was also noticed that there was at least 60% ligand depletion. The amount
of ligand depletion that was calculated from the model exceeds that encoun-
tered experimentally, probably because the defined concentration of albumin
in the model is higher than that present in the experimental system. It should
be noted, however, that if SHBG was present at the concentrations that have
been published for HepG2 cells, between 0.63nM and 0.98nM intracellular
[137, 142], it is still possible to reach saturating conditions. From the results
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of the modelling it was thus concluded that the reason that saturation con-
ditions were not reached in the Hep89 experimental system was because of
the presence of albumin.
The results of the saturation binding assay, performed using human preg-
nancy plasma diluted 25 times, showed that it was not possible to determine
the binding constants for E2 binding SHBG using this experimental system.
It was hypothesized that the presence of albumin was interfering with the
binding assay.
To determine whether albumin was interfering with the binding of E2 to
SHBG, the experimental system proposed by Hammond [180] was first mod-
elled. The results of this model show that when plasma was diluted 200
times, the binding constants for SHBG binding DHT can be determined. If
the plasma was diluted 100 times it was not possible to determine the bind-
ing constants for SHBG, as Hammond reported. A possible reason for this
is that when plasma was diluted 100 times ligand depletion in excess of 10%
was encountered.
The results of the model describing the binding of E2 to SHBG in human
plasma, diluted 25 times, showed that over 40% of E2 was bound. These re-
sults are similar to those of the experimental system where it was found that
between 32% and 43% of E2 was bound. Using the model it was possible to
calculate that if the plasma was diluted 200 times there would be have been
less than 10% ligand depletion, however saturation conditions would not have
been reached. With respect to the influence that albumin has on the binding
of E2 to SHBG it was possible to show that if no albumin was present then
saturating conditions would have been reached if the plasma was diluted 200
times. It should be noted that even in the plasma was diluted 200 times
it would not have been possible to determine the Kd for SHBG, only the
Kd app as albumin binds E2 and lowers the equilibrium concentration of E2.
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The binding of E2 by albumin is supported in the literature as it has been
found to bind between 58.3% and 73.8% in females and males respectively
in human plasma [158].
If one were to recommend an experimental system to determine the bind-
ing constants for SHBG when binding E2, using human pregnancy plasma,
it is recommended to rather use the experimental system that Dunn et al
[158] used. In this experimental system concanavalin A-Sepharose was used
to isolate SHBG from human pregnancy plasma. The pure SHBG solution
can then be used to determine the binding constants for SHBG binding E2.
When examining the results of the promoter reporter gene assays it was
noted that the ligand independent transactivation of the ERE reporter gene
constructs was problematic. This is not a problem that has been reported in
the literature surrounding the use of COS-1 cells to perform the same type of
promoter reporter gene assays. Korach et al [197] and Pennie et al have both
been able to use COS-1 cells as experimental systems in which to determine
the effect of E2 on estrogenically sensitive reporter genes. In Korach’s article
the role that the ERE plays in changing the conformation that ER-α adapts,
when binding the ERE, was elucidated. It was shown that the sequence of
the ERE can have an indirect influence on the cofactors that are recruited
and in so doing also have an affect on the level of transactivation, via the
ligand bound ER-α. The work of Pennie [183] showed that the level of trans-
activation, via the ligand bound ER-α, of an ERE depends on the cellular
environment as well as the ligand that ER-α bound.
In conclusion it has been shown that the aims of this project as stated were
not accomplished due to a number of problems that were encountered. It has
been possible to show why the binding constants for ER-α and SHBG were
not determined using the Hep89 and human pregnancy plasma experimental
systems. With respect to the promoter reporter gene assay studies it is still
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not clear why there was ligand independent transactivation in the COS-1 cell
experimental system. It has also become clear from this study that it may
not just be the influence that SHBG has on the binding of E2 to ER-α but
that other factors will have to be taken into account in further studies.
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Appendix A
Optimisation of protocols using
the Calcium Phosphate
transfection technique
The aim of the experiments described in this section of work was to develop
an experimental system in which the effect of E2 on an estrogenically sensi-
tive reporter gene could be studied.
As COS-1 cells had to be transfected the available transfection processes
were evaluated on the basis of reproducibility, cost and availibility of reagents.
Based on these decisions it was decided that either the calcium phosphate or
DEAE-Dextran transfection method could be used to transfect COS-1 cells.
Initially it was decided to investigate the calcium phosphate transfection
method [198].
A.1 Optimisation of transfection
The aim of the following experiments was to optimize the transfection process
with respect to COS-1 cells. To accomplish this the method was optimized
with respect to the number of cells seeded and the amount of DNA used in
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the transfection process. The role of a glycerol shock, as suggested by the
protocol [198], was studied to ascertain whether it was necessary for optimal
transfection efficiency, Table A.1.
Table A.1: Conditions used for optimisation of calcium phosphate
transfection.
Number of cells seeded per well 1,1.5 and 2×105 cells
Amount of DNA per well 1.73 and 2.41
Effectiveness of shocking 10% glycerol shock vs no shock
COS-1 cells were seeded at varying densities; 1×105, 1.5×105 and 2×105;
cells per well in 24 well plates, transfected using the calcium phosphate
transfection method with varying amounts of DNA and finally exposed to
a 10% glycerol shock or a PBS wash in place of the shock.
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As COS-1 cells were transiently transfected the results of the experiments
had to be normalized and it was decided to normalize the results using the
results obtained from a β-galactosidase reporter that was co-transfected. The
use of Neogal and pSV-β-galactosidase β-galactosidase reporter genes were
studies as well.
The results of these experiments are shown in Figure A.1. From the results of
these experiments it was concluded that optimal transfection efficiency was
obtained when COS-1 cells were seeded at a density of 1×105 cells per well
in 24 well plates and transfected with 1.73µg DNA or 2.41µg DNA. With
respect to the use of a 10% glycerol shock during the transfection process it
was found that this was not necessary for optimal transfection. It was also
decided that in future pSV-β-galactosidase will be used as a β-galactosidase
reporter gene.
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Figure A.1: Optimisation of calcium phosphate transfection. COS-1
cells were maintained and transfected with either 1.73µg or 2.41µg DNA as
described in Appendix C.2.1 and C.3.1. Cells were transfected using either
Neogal or pSV-β-galactosidase as β-galactosidase reporter genes. (a) COS-1 cells
transfected with Neogal and exposed to a 10% glycerol shock, (b) COS-1 cells
transfected with Neogal, the cells were not exposed to a 10% glycerol shock., (c)
COS-1 cells transfected with pSV-β-galactosidase and exposed to a 10% glycerol
shock, (d) COS-1 cells transfected with pSV-β-galactosidase, the cells were not
exposed to a glycerol shock. Results are shown as the average with standard
errors for triplicate samples.
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A.2 Optimisation of transactivation
The aim of the following experiments was to determine the level of trans-
activation of an ERE, via the ligand bound ER-α, using COS-1 cells as the
experimental system. The experimental system was optimized with respect
to the following: plasmid ratios (ERE.tk-luc, β-galactosidase reporter gene,
and ER-α), the medium and supplements used
Initially COS-1 cells were maintained and transfected as described in Ap-
pendix C.3.1 with 1.73µg of DNA, Table C.3. The results of this experiment
are shown in Figure A.2. From the results of this experiment it was deter-
mined that there was ligand independent transactivation. This can be seen
when comparing samples that were exposed to 1×10−5M E2 to those only
exposed to ethanol. It was also noted that the β-galactosidase reporter gene,
pSV-β-galactosidase, seemed to be sensitive to the presence of estrogenic
compounds. With this in mind it was decided to search the literature and it
was noted that the ratio of plasmids that were used in the experiment, Table
C.3 was not the same as that in the literature, Table C.3.
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Figure A.2: Optimisation of transactivation using ERE.tk-luc as ERE
reporter gene (Normalized results). COS-1 cells were seeded and
transfected using the calcium phosphate transfection technique with a total of
1.73µg of DNA consisting of 1.02µg ER-α, 0.58µg ERE.tk-Luc and 0.13µg
β-galactosidase reporter gene as described in Appendix C.3.1. The cells were
grown for a further 24 hours after which the 10−5M E2 was added and the cells
incubated for a further 24 hours. The cells were then lysed and frozen overnight
at -20◦C and the lysate analyzed for the presence of luciferase and
β-galactosidase and protein. Control 1 is transfection with only the addition of
EtOH as a control, Control 2 is where there was no transfection. Luciferase
values were normalized by dividing by the β-galactosidase values. Results are
shown as the average with standard errors for triplicate samples.
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Figure A.3: Optimisation of transactivation using ERE.tk-luc as ERE
reporter gene (β-galactosidase results). COS-1 cells were seeded and
transfected using the calcium phosphate transfection technique with a total of
1.73µg of DNA consisting of 1.02µg ER-α, 0.58µg ERE.tk-Luc and 0.13µg
β-galactosidase reporter gene as described in Appendix C.3.1. The cells were
grown for a further 24 hours after which the 10−5M E2 was added and the cells
incubated for a further 24 hours. The cells were then lysed and frozen overnight
at -20◦C and the lysate analyzed for the presence of β-galactosidase. Control 1 is
transfection with only the addition of EtOH as a control, Control 2 is where
there was no transfection. Results are shown as the average with standard errors
for triplicate samples.
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The aim of the following experiment was to determine whether changing
the ratios of plasmids used would have an influence on the transactivation of
the ERE.tk-luc reporter gene. The secondary aim was to determine whether
Neogal, a β-galactosidase reporter, was sensitive to the presence of estrogenic
compounds.
COS-1 cells were transfected with a total of 1.73µg DNA using the calcium
phosphate transfection method. The ratio of plasmids used is shown in Table
C.3. The following controls were also included:
• Control 1- COS-1 cells were transfected with the ERE.tk-luc and β-
galactosidase reporter genes as well as the pCDNA-3-ER-α plasmid.
The cells were only exposed to ethanol as a test compound. This is a
control for the presence of ligand independent transactivation.
• Control 1- COS-1 cells were transfected with the ERE.tk-luc and β-
galactosidase reporter genes. The cells were only exposed to ethanol
as a test compound. This is a control for the presence of receptor
independent transactivation
• COS-1 cells were not transfected. The cells were only exposed to
ethanol as a test compound. This is a control for the constitutive
expression of the ERE reporter gene.
As can be seen from the results, Figure A.4, there seemed to be ligand in-
dependent transactivation as there was no difference between the samples
that were exposed to varying concentrations E2 (1×10−5M, 1×10−7M or
1×10−10M) or ethanol. With respect to the use of Neogal as a β-galactosidase
reporter it did not seem that Neogal was sensitive to the presence of estro-
genic compounds, Figure A.5. From the results of these experiments it was
concluded that there was either ligand and receptor independent transactiva-
tion when using ERE.tk-luc as a luciferase reporter gene or that the calcium
phosphate transfection technique could not be used as the transfection effi-
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ciency was too low. As a results it was decided to investigate the use of the
DEAE-Dextran transfection technique.
] M2Log [E
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 














 
 
 
 
 
 
 
 
 
 
 
 
 













  
  
  
  
  
  
  
  
  
  
  











 
 
 
 
 
 
 
 
 
 
 
 
 
 














 
 
 
 
 
 
 
 
 
 
 
 
 
 














  
  
  
  
  
  
  
  
  
  
  
  
  
  














Stoica Neogal
 0.2
 0.4
 0.6
 0.8
 1
 1.2
Co
nt
ro
l 3
Co
nt
ro
l 2
Co
nt
ro
l 1
−
10−7−5
Lu
ci
fe
ra
se
 ±
 S
EM
, n
=3
Neogal
Green Neogal
 0
Figure A.4: Optimisation of DNA ratios used in transactivation
studies (Luciferase values). COS-1 cells were seeded and transfected using
the calcium phosphate transfection technique with a total of 1.73µg of DNA The
ratios of DNA used in the experiments were as follows: Original (1.03µg ER-α,
0.58µg ERE.tk-Luc, 0.12µg pSV-β-galactosidase), Stoica (0.21µg ER-α, 1.08µg
ERE.tk-luc, 0.08µg pSV-β-galactosidase, 0.36µg pGL2-Basic), Green (0.216µg
ER-α, 1.08µg ERE.tk-Luc, 0.426µg pSV-β-galactosidase). The cells were grown
for a further 24 hours after which the 11×10−5M E2 was added and the cells
incubated for a further 24 hours. The cells were then lysed and frozen overnight
at -20◦C and the lysate analyzed for the presence of luciferase and
β-galactosidase and protein. Control 1 is transfection with only the addition of
EtOH as a control, Control 2 is where there was no transfection. Luciferase
values were normalized by dividing by the β-galactosidase values. Results are
shown as the average with standard errors for triplicate samples.
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Figure A.5: Optimisation of DNA ratios used in transactivation
studies (β-galactosidase values). COS-1 cells were seeded and transfected
using the calcium phosphate transfection technique with a total of 1.73µg of
DNA The ratios of DNA used in the experiments were as follows: Original
(1.03µg ER-α, 0.58µg ERE.tk-Luc, 0.12µg pSV-β-galactosidase), Stoica (0.21µg
ER-α, 1.08µg ERE.tk-luc, 0.08µg pSV-β-galactosidase, 0.36µg pGL2-Basic),
Green (0.216µg ER-α, 1.08µg ERE.tk-Luc, 0.426µg pSV-β-galactosidase). The
cells were grown for a further 24 hours after which the 1×10−5M E2 was added
and the cells incubated for a further 24 hours. The cells were then lysed and
frozen overnight at -20◦C and the lysate analyzed for the presence of
β-galactosidase. Control 1 is transfection with only the addition of EtOH as a
control, Control 2 is where there was no transfection. Results are shown as the
average with standard errors for triplicate samples.
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Appendix B
Optimisation of protocols using
DEAE-Dextran transfection
technique
The aim of the following experiments was to determine whether the DEAE-
Dextran transfection technique was suitable for the transient transfection of
COS-1 cells. The DEAE-Dextran transfection protocol was chosen because
it was not expensive and had been shown to be reproducible. Once it had
been shown that COS-1 cells could be transfected using the DEAE-Dextran
transfection technique, promoter reporter studies could be performed.
B.1 Optimisation of transfection
The aim of the following experiments was to optimize the transient transfec-
tion of COS-1 cells using the DEAE-Dextran transfection technique.
The protocol was optimized with respect to the amount of DNA used, num-
ber of COS-1 cells seeded and the amount of DEAE-Dextran used in the
protocol, Table C.5.
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B.1 Optimisation of transfection
COS-1 cells were maintained and transfected as described in Appendix C.3.2
after which the cells were exposed to 1×10−5M or ethanol and assayed for
the presence of luciferase and β-galactosidase. The results of this experiment,
Figure B.1, showed that optimal transfection efficiency was obtained when
COS-1 cells were seeded at a density of 5×104 cells per well in 24 well plates
and transfected using 34.45ng of DNA and 6910ng of DEAE-Dextran. It was
noted that the transfection efficiency was not greatly affected by cell number
and thus it was decided that in future 6.9×104 would be seeded per well.
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Figure B.1: Optimisation of DEAE-Dextran transfection in COS-1
cells. COS-1 cells were plated at varying densities per well (5×104, 6.9×104 and
1×105 cells per well in 24 well plates) and incubated at 37◦C, 5% CO2 and 90%
humidity. After 24 hours the cells were transfected using the DEAE-Dextran
transfection technique whilst varying the amounts of DEAE-Dextran (between
3450 and 13820ng per well) and DNA (between 34.45 and 345.45ng) per well,
using the ratios of Stoica, Table C.3, and the cells incubated for a further 24
hours. The cells were then exposed to 1×10−5E2 in DMEM containing 10 %fetal
calf serum and 1% Pencillin-Streptomycin for 24 hours. The medium was then
removed and the cells lysed after which the samples were frozen overnight at
-20◦C. The samples were then analyzed for the presence of luciferase and
β-galactosidase. Results are shown as the average with standard errors for
triplicate samples.
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B.2 Optimisation of transactivation
The aim of the following studies was to determine the level of transactiva-
tion of the ERE.tk-luc, via the ligand bound ER-α, using COS-1 cells as an
experimental system. The experimental approach used was to determine the
effect that various medium supplements (fetal calf serum, stripped fetal calf
serum and no fetal calf serum), as well as the presence of phenol red in the
medium, had on the transactivation of an ERE. The time after transfection
that the medium was changed was also studied to determine the effect. The
use of various β-galactosidase reporter genes, pSV-β-galactosidase, Neogal
and pCMV-β-galactosidase, was also studied.
Initially the time after transfection that the medium was changed was stud-
ied. The medium was changed from DMEM containing 10% fetal calf serum
to one of the following:
• DMEM containing either fetal calf serum, stripped fetal calf serum or
no fetal calf serum.
• DMEM containing no phenol red either fetal calf serum, stripped fetal
calf serum or no fetal calf serum as supplements.
The medium was changed either 12 or 24 hours after transfection. If the
medium was changed 12 hours after transfection then 1×10−5M E2 or ethanol
(0.01%) was added to the cells after a further 12 hours. The same conditions
were used if the medium was changed 24 hours after transfection, the only
difference being that the test compounds would be added only after a further
24 hours. The reason for these changes was to determine whether there was
a difference in the expression levels of luciferase when comparing 12 and 24
hours. The results of this experiment, Figure B.2, showed that there was
no difference in the results if the medium was changed 12 or 24 hours after
transfection. With respect to the use of DMEM or DMEM containing no
phenol red, it was found that higher levels of transactivation were induced in
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the presence of phenol red. The results pertaining to the use of the various
medium supplements showed that maximal transactivation was reached in
the presence of fetal calf serum, whilst when no fetal calf serum was used
the levels of transactivation were lower. It was however noted from the
results that pSV-β-galactosidase was sensitive to the presence of estrogenic
compounds, Figure B.3. With this in mind it was decided to repeat the
experiment using either Neogal or pCMV-β-galactosidase as β-galactosidase
reporter genes.
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Figure B.2: Optimization of transactivation studies in COS-1 cells.
COS-1 cells were seeded and transfected as described in Appendix C.4. The
medium was changed to DMEM with or without phenol red containing various
supplements (fetal calf serum, stripped fetal calf serum and no fetal calf serum)
either 12 or 24 hours after transfection. After a further 24 hours either 1×10−5M
E2 or ethanol was added to the medium and the cells incubated for a further 24
hours.The samples were assayed for the presence of β-galactosidase and luciferase
as described in Appendix C.4. Control 1: Transfection with ERE, ER-α and
ethanol used as test compounds. Control 2: Transfection with ERE,
β-galactosidase reporter and ethanol used as test compounds. Control 3: No
transfection and ethanol used as test compounds. Results are shown as the
average with standard errors for triplicate samples.
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Figure B.3: Optimization of transactivation studies in COS-1 cells,
β-galactosidase values. COS-1 cells were seeded and transfected as described
in Appendix C.4. The medium was changed to DMEM with or without phenol
red containing various supplements (fetal calf serum, stripped fetal calf serum
and no fetal calf serum) either 12 or 24 hours after transfection. After a further
24 hours either 1×10−5M E2 or ethanol was added to the medium and the cells
incubated for a further 24 hours.The samples were assayed for the presence of
β-galactosidase as described in Appendix C.4. Control 1: Transfection with
ERE, ER-α and ethanol used as test compounds. Control 2: Transfection with
ERE, β-galactosidase reporter and ethanol used as test compounds. Control 3:
No transfection and ethanol used as test compounds. Results are shown as the
average with standard errors for triplicate samples.
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The aim of the following experiments was to determine the level of trans-
activation of the ERE.tk-luc reporter gene, via ligand bound ER-α. The
secondary aim was to determine whether pCMV-β-galactosidase or Neogal
could be used as β-galactosidase reporters. The experimental procedures
used were the same as those reported above, the only difference being the
use of different β-galactosidase reporters. The results of these experiments
where pCMV-β-galactosidase was used as a β-galactosidase reporter, are
shown in Figures B.4 and B.5. The results showed that maximal levels of
transactivation, 250 relative light units, were obtained in the presence of
DMEM containing using fetal calf serum as a supplement. The minimum
level of transactivation, 125 relative light units, was obtained when DMEM
containing phenol red and no fetal calf serum was used. With respect to
the use of pCMV-β-galactosidase it was noted that there were higher levels
of expression in samples that were not transfected with a β-galactosidase
reporter than samples that were transfected, Figure B.5. As a result of this
not much can be said about the influence of estrogenic compounds on the
pCMV-β-galactosidase reporter gene. With respect to the results, Figure
B.6, relating to the samples which were transfected with the Neogal reporter
gene the following can be said. It was noted that there was receptor inde-
pendent transactivation. This was noticed when comparing the samples that
were transfected with ER-α as compared to those that were not transfected
with ER-α. Once again there was a problem with the β-galactosidase values
in that higher levels of expression were being reported in the absence of the
Neogal reporter than when Neogal was present.
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Figure B.4: Optimisation of transactivation using the
pCMV-β-galactosidase reporter gene (Luciferase results). COS-1 cells
were seeded and transfected with a total of 34.45ng DNA (ratios used were those
of Stoica Table C.3) as described in Appendix C.4. After 24 hours the medium
was changed to either DMEM containing or not containing phenol red and
various supplements and 24 hours later 1×10−5M E2 or ethanol was added. The
cells were lysed and the samples assayed for the presence of luciferase. The type
of medium and supplements which the cells were exposed to after transfection
were as follows: a) COS-1 cells were grown in DMEM containing phenol red and
10% fetal calf serum, b) COS-1 cells were grown in DMEM containing no phenol
red and 10% fetal calf serum, c) COS-1 cells were grown in medium containing
phenol red and 10% stripped fetal calf serum, d) COS-1 cells were grown in
DMEM containing no phenol red and 10% fetal calf serum. After this the cells
were incubated for a further 24 hours after which the medium was removed and
the cells lysed. The samples were then frozen overnight after which they were
analyzed for the presence of luciferase. Control 1: Transfection with ERE, ER-α
and ethanol used as test compounds. Control 2: Transfection with ERE,
β-galactosidase reporter and ethanol used as test compounds. Control 3: No
transfection and ethanol used as test compounds. Results are shown as the
average with standard errors for triplicate samples.
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Figure B.5: Optimisation of transactivation using the
pCMV-β-galactosidase reporter gene (β-galactosidase results). The
same methodology was used as described in Figure B.4, only the β-galactosidase
results are shown. Results are shown as the average with standard errors for
triplicate samples.
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Figure B.6: Optimisation of transactivation using the Neogal
β-galactosidase reporter gene (Luciferase results). COS-1 cells were
transfected and treated as described in Figure B.5. Neogal was used as a
β-galactosidase reporter gene instead of pCMV-β-galactosidase. Results are
shown as the average with standard errors for triplicate samples.
140
B.2 Optimisation of transactivation
In an attempt to determine whether the ligand independent transactiva-
tion of the ERE.tk-luc reporter was due to the amount of reporter gene or
ER-α expressed it was decided to determine whether using a higher amount
of DNA in the transfection process made a difference, The use of DMSO as a
solvent was also studied. The results of these experiments are shown in Fig-
ure B.7. From these results it was concluded that the time after transfection
that the medium was changed did not make a difference and it was decided
in future the medium would be changed 24 hours after transfection. With
respect to the use of DMSO as a solvent it was found that this did not have
an influence as there was still ligand independent transactivation as can be
seen when comparing samples that were exposed to E2 to those exposed to
only ethanol.
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Figure B.7: Optimisation of amount of DNA to use in transactivation
experiments. COS-1 cells were seeded at 7×104 cells per well and transfected
using the DEAE-Dextran transfection technique as described in Appendix C.4.
Modifications to the transfection protocol included varying the amount of DNA
used, between 150ng and 850ng (ratios used were those of Stoica, Table C.3).
The growth medium was changed to DMEM containing no phenol red and 10%
stripped fetal calf serum either 6, 12 or 24 hours after transfection. After a
further 24 hours the cells were exposed to 1×10−5M E2 or DMSO (as a control)
after which the samples assayed for the presence of β-galactosidase and luciferase.
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Appendix C
Methods
C.1 Plasmid isolation
C.1.1 Preparation of electro-competent cells
Escherichia coli (E. coli) cells (JM109) plated on Luria broth (LB) agar
plates were incubated overnight at 37◦C. A single colony was then picked
and incubated in 50ml SOB medium overnight at 37◦C shaking at 180rpm.
Of the overnight culture, 5ml was added to 500ml of SOB and the resultant
culture was incubated at 37◦ shaking at 180rpm until a cell density with an
OD550 of 0.8 was reached. These cultures were subsequently transferred to
chilled A10 centrifuge bottles and concentrated by centrifugation at 3500rpm
for 15 minutes at 4◦C. The supernatant was discarded and the cell pellet
resuspended in 200ml of MQ-H2O and centrifuged at 3500rpm, 4
◦C for 15
minutes. This step was repeated twice after which the cells were washed twice
with an ice-cold 10% glycerol solution using the same procedure, resuspended
in 4ml of 100% glycerol solution and frozen at -80◦C.
C.1.2 Transformation of electro-competent cells
Bacterial cells were transformed using electroporation as previously described
[199, 200, 201]. Electro-competent E. coli cells were diluted 1:1 with 10%
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glycerol and 40µl of the prepared solution was added to a chilled eppindorf
tube (1.5ml). A total of between 10 and 20ng of DNA was added to the cells
and the solution was placed in a electroporation cuvette (model 610,TX).
The cuvette was then placed into the gene transformer and a quick pulse was
applied to the sample, after which the sample was transferred to 1ml SOC
and incubated at 37◦C shaking at 225rpm for 1 hour. Cultures were then
streaked out on LB-Ampicillin (LB-AMP) plates and incubated overnight at
37◦C.
C.1.3 Extraction of plasmid DNA
Concert Maxi Prep
The method followed for this protocol is the same as the Concert R©High
Purity plasmid Purification systems manual supplied by Life Technologies R©.
C.2 Tissue culture
C.2.1 Maintenance of COS-1 cells
COS-1 cells were maintained in DMEM containing 10% fetal calf serum and
1% Penicillin-Streptomycin. COS-1 cells, grown at 37◦C, 90% humidity and
5% CO2, were spilt twice a week. To split cells the medium was aspirated
and 1ml trypsin was added. After two minutes the flask was lightly tapped
to loosen the cells. The suspended cells were then transferred to DMEM
(no fetal calf serum) and centrifuged for 5 minutes at 3000g to remove the
trypsin. The cells were subsequently suspended in DMEM plus 10% fetal
calf serum and again plated in 75cm2 tissue culture flasks.
C.2.2 Maintenance of Hep89 cells
Hep89 cells were maintained in DMEM containing 10% fetal calf serum,
0.1mM non-essential amino acids, 1.0mM sodium pyruvate. The cells were
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grown at 37◦C, 90% humidity and 5% CO2. Cells were split as described
in the previous section. The cells were subsequently resuspended in DMEM
containing 10% fetal calf serum, 0.1mM non-essential amino acids and 1.0mM
sodium pyruvate and again plated in 75cm2 tissue culture flasks.
C.3 Optimisation of transfection
C.3.1 Optimisation of transfection using calcium phos-
phate as transfection method
The transfection method used is this study was based on a standard calcium
phosphate transfection protocol [198].
The protocol was, however, optimised for this study by changing the fol-
lowing conditions: number of cells plated (1×105,1.5×105,2×105 cells per
well in a 24 well plate), amount of DNA (1.73µg and 2.41µg of DNA per
well) and finally the use of a glycerol shock.
The general transfection protocol for 1×105 cells per well and 1.73µg to-
tal DNA follows, Table C.2.
COS-1 cells plated in 24 well (Nunc) plates, at a density of 1×105 cells per
well, and grown for 24 hours in DMEM containing 10% fetal calf serum and
1% Penicillin-Streptomycin. Four hours before transfection the medium was
replaced with DMEM containing 1% Penicillin-Streptomycin. The following
transfection solutions were prepared, Table C.1.
Solution A was slowly added, drop wise, to solution B and the resulting
mixture left at room temperature for 45 minutes until a fine precipitate had
developed. A total of 34µl of transfection solution was then added to each
well of a 24 well plate and the cells incubated for 16 hours. The medium
145
C.3 Optimisation of transfection
was then aspirated and the cells washed twice with 1ml PBS (0.137M NaCl,
0.0027M KCl, 0.0043M Na2HPO4, 0.00147M KH2PO4, pH 7.0) and if re-
quired exposed to a glycerol shock (10% glycerol in PBS), followed by incu-
bation for a further 24 hours in complete medium.
Table C.1: Preparation of calcium phosphate transfection solutions.
Solution A
CaCl2 (2.5M) 1.7µl
DNA 1.73µg
MQ-H2O (make final volume up to 17µl)
Solution B
2× HEPES buffered saline 17µl
100×phosphate buffer 0.34µl
(70mM Na2HPO4, 70mM NaH2PO4)
MQ-H2O (make final volume up to 17µl)
Table C.2: Composition of the DNA solution used in optimisation of
calcium phosphate transfection.
Sample Control
ng
β-galactosidase 0.12 0
pGL2-Basic 1.61 0
Total 1.73 0
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Table C.3: Variation of the composition of DNA content during
transactivation experiments.
Type of DNA Percentage of total
Original ER-α 59%
ERE 34%
β-galactosidase 7%
Stoica [202] ER-α 12.49%
ERE 62.42%
β-galactosidase 4.62%
pGL2-basic 20.47%
Green [203] ER-α 15%
ERE 49.71%
β-galactosidase 34.68%
Table C.4: Various controls that were included in transactivation
experiments.
ER-α ERE.tk-luc β-galactosidase Test compound
Control 1 + + + EtOH
Control 2 - + + EtOH
Control 3 - - - EtOH
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C.3.2 Optimisation of transfection using DEAE-Dextran
as transfection method
The transfection method used in this study was based on a standard DEAE-
Dextran transfection protocol [182]. This protocol was, however, optimised
for this study by changing the following conditions: Number of COS-1 cells
plated, amount of DNA and DEAE-Dextran, Table C.5.
Table C.5: Conditions for optimisation of DEAE-Dextran transfection.
DNA 0.34, 150 or 300ng
DEAE-Dextran 3.45, 6.91 or 13.82µg/ml
Cell number 5×104, 7×104 or 1×105 cells per well in a 24 well plate
Transfection in 24 well plates
COS-1 cells were plated in 24 well plates, at a varying densities per well,
and grown for 24 hours in DMEM containing 10% fetal calf serum and 1%
Penicillin-Streptomycin. The transfection solution was prepared by adding
chloroquine (final concentration 100µM) to DMEM without fetal calf serum,
after which the DNA (final amount between 34.45 and 150ng/µl per 250µl
transfection solution) was added and finally DEAE-Dextran (final concen-
tration 13.82µg/ml) was added to the solution. The transfection solution
was mixed by vortexing, after which 250µl was placed on the cells in each
well (of which the medium had been removed) and the cells incubated for
1 hour at 37◦C, 90% humidity and 5% CO2. The transfection solution was
then removed and DMEM containing 10% fetal calf serum and 1% Penicillin-
Streptomycin was added after which the cells were then incubated for a fur-
ther 24 hours.
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Transfection in 10cm3 plates
COS-1 cells were plated at a density of 2×106 cells per plate and incubated
for 24 hours. COS-1 cells were transfected using the DEAE-Dextran trans-
fection method as described above. The protocol was, however, modified
by increasing amount of DNA to 4.34µg per 7.14ml of transfection solution,
which was used per 10cm3 plate.
C.4 Optimisation of transactivation
COS-1 cells were plated in either 24 well plates (7×104 cells per well) or
10cm3 plates (2×106 cells per plate) in DMEM containing 10% fetal calf
serum and 1% Penicillin-Streptomycin and incubated for 24 hours at 37◦C,
90% humidity and 5% CO2.
Cells were then transfected using either the calcium phosphate , section C.3.1
or DEAE-Dextran, section C.3.2, transfection method and grown for a fur-
ther 24 hours.
When COS-1 cells were plated in a 24 well plate then the medium was
changed to DMEM without phenol red and grown for a further 24 hours
at 37◦C, 90% humidity and 5% CO2. The growth medium was then changed
to DMEM containing no phenol red with stripped fetal calf serum after which
varying concentration of E2 (between 1×10−5 and 1×10−12M or EtOH (final
amount of EtOH 0.1% in both scenarios) was added. After 24 hours the
medium was removed and the cells washed three times with 1ml PBS (pH
7.0) after which the PBS was removed and 50µl Galactostar lysis buffer was
added and the samples frozen overnight at -20◦C. If COS-1 cells were plated
in 10cm3 plates then the cells were replated at a density of 7×104 cells per
well in a 24 well plate and incubated for 24 hours at 37◦C, 90% humidity
and 5% CO2. The protocol was the same from here on as that of the cells
that were plated at 7×104 cells per well.
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C.4.1 Conditions for optimisation
There were a number of conditions that were considered when trying to op-
timize the experimental conditions for transactivation experiments, they are
as follows:
The relative composition of the DNA was altered, Table C.3, type of medium
(DMEM either containing phenol red or without phenol red), supplements
(fetal calf serum, stripped fetal calf serum (prepared according to the pro-
tocol of Hibbert [204]), no fetal calf serum), type of ERE reporter gene
used (ERE.tk-Luc vs ERE-vit), and finally the times at which medium was
changed during the experiment.
C.4.2 Optimisation of β-galactosidase reporter
To analyse the transactivation results the luciferase values had to be nor-
malized using β-galactosidase. The use of various β-galactosidase reporter
genes were examined, as well as their sensitivity to the presence of estro-
genic compounds. The method was the same as above, except that the cells
would be transfected with only a β-galactosidase reporter (Neogal, pSV-β-
galactosidase or pCMV-β-galactosidase, no other DNA was used)
C.5 Whole cell binding of 17-β-estradiol to
the human ER-α
C.5.1 General method
C.5.2 COS-1 cells
COS-1 cells were plated in 10cm3 plates at a density of 2×106 cells/plate
in DMEM containing 10% fetal calf serum and 1% Penicillin-Streptomycin.
Cells were grown for 24 hours at 37◦C, 90% humidity and 5% CO2, after
150
C.5 Whole cell binding of 17-β-estradiol to the human ER-α
which they were transfected using the DEAE-Dextran transfection method
as described in section C.3.2. The total amount of DNA used during trans-
fection was 4.34µg per plate 1. After transfection the cells were grown for 24
hours at 37◦C, 90% humidity and 5% CO2. COS-1 cells were then replated
at a density of 1×105 cells per well in 12 well plates and grown for 24 hours
after which the medium was changed to DMEM (without phenol red) and
1% Penicillin-Streptomycin.
Competitive binding assay
After a further 24 hours growth the medium was removed and replaced with
1ml DMEM containing no phenol red and 0.5nM 3H-E2 (2,4,6,7
3H-17-β-
estradiol, SA 83Ci/mmol supplied by AEC-Amersham cat. No TRK 322)
and increasing amounts of unlabelled E2 (final concentration between 1×10−5
and 1×10−13, Sigma Cat. No. E-2758) made up in EtOH (final concentra-
tion 0.01%). Following a 10 hour incubation, at 37◦C, 5% CO2 and 90%
humidity, the medium was removed and the cells washed three times with
ice-cold PBS-(0.2%) BSA, at 4◦C for 15 minutes per wash, after each wash
the PBS was removed. After the wash step had been finished 100µl of lysis
buffer was added to each well and the samples frozen overnight at -20◦C. The
samples were then thawed and scraped after which 80µl of the sample was
added to 3ml scintillation fluid (Zinsser analytic quick safe flow 2 supplied
by Bioteknik cat. no. 1004000) and the remaining 20µl was kept for protein
determinations, using the Bradford technique. The wells were then washed
out with a further 100µl of lysis buffer, which was then also added to the
scintillation fluid. The samples were then counted in a Beckman Scintillation
Counter, which was set up to detect the presence of tritium.
10.5208µg ER-α, 0.102µg ERE-vit, 2.34µg pGL2-Basic and 0.17µg pCMV-β-
galactosidase
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C.5.3 Hep89 cells
Competitive binding assay
The protocol used for competitive binding assays in Hep89 cells was based
on the protocol used for COS-1 cells, however the cells were not transfected
as they had been stably transfected with ER-α and 1nM of 3H-E2was used..
Saturation binding assay
The same method was followed as for the Hep89 competitive binding assay
except that cells were incubated in the presence of varying amounts of 3H-E2
in the presence/absence of 1×10−5M unlabelled E2. After a further 24 hours
of growth the medium was removed and replaced with medium that contained
varying amounts of 3H-E2 (between 0.248 and 75nM in the presence/absence
of 1×10−5M E2. Cells were then incubated for a further 10 hours, washed,
lysed and frozen. The rest of the method follows as above.
C.6 Human pregnancy plasma
C.6.1 Optimisation of system
The method used in this study was based on that of Hammond [181]. The
protocol was, however, optimised by changing the following conditions: In
the protocol no excess of testosterone was used. Human pregnancy plasma
stored at -80◦C until used.
Human pregnancy plasma was stripped of endogenous steroids by incubat-
ing 20µl in the presence of 1980µl of dextran coated charcoal (DCC) for 30
minutes at room temperature on the “the belly dancer” at a moderate speed
(supplied by Tovall life sciences, SA), after which it was concentrated by cen-
trifuging at 13000g for 10 minutes at room temperature and the supernatant
removed for use in experiments.
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Total binding was determined by adding 100µl supernatant (stripped hu-
man pregnancy plasma diluted 1:100 using 0.01M PBS), 100µl 0.01M PBS
containing the required amount of 3H-E2 and 0.1% EtOH, diluted in 100µl
PBS, together in an 2ml eppi, the final volume being 300µl.
Non specific binding was determined in the same way except that 1×10−5M
E2, diluted in EtOH (0.1% final volume), was added.
Samples, defined as the plasma steroid solution in an eppindorf, were then
vortexed and incubated on a “belly dancer“ for 10 hours at room temper-
ature. The samples were then placed in an ice/EtOH sludge (0◦C) for 15
minutes. A total of 750µl of ice cold DCC was then added to each sample
with a repette, as this had to be done in less than a minute the samples
were handled in batches of 12 samples per batch. After addition of DCC,
the samples were incubated for a further 10 minutes at 0◦C. The DCC sep-
arated from the supernatant by spinning down the samples at 13000g, 0◦C
for 15 minutes. A total of 850µl of the supernatant was removed and added
to 3ml scintillation fluid and assayed for the presence of 3H-E2in a Beckman
Scintillation counter.
Controls used in the experiment were as follows:
No SHBG
No SHBG + DCC (control for DCC stripping)
SHBG + EtOH (control for E2)
C.6.2 Competitive binding assay
The method used for these experiments was the same as above, however the
samples were exposed to either E2, 1×10−5 to 1×10−12 or EtOH and a further
control, the absence of 3H-E2, was included.
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C.6.3 Saturation binding assay
Optimisation
The method used was based on that described above, however, certain mod-
ifications to the protocol were performed as described below. The amount
of SHBG in the samples was varied by changing the dilution factor between
100, 50 and 25× in the initial dilution step, and the amount of DCC added
was changed according to the dilution (final volume remained constant) thus
is the serum was diluted 25× then the amount of DCC was increased by
a factor of four. The protocol used in these experiments was based on the
method used in the competitive binding assay using HPP, however, certain
modifications were made: The samples were incubated, at room tempera-
ture, in the presence of varying amounts of 3H-E2 (between 0.25nM 30nM)
and presence/absence of unlabelled E2 (1×10−5M).
C.7 Thin layer chromatography
C.7.1 COS-1 cells
COS-1 cells were plated in 10cm3 plates at a density of 2×106 cells per plate
in DMEM containing 10% fetal calf serum, 1% Penicillin-Streptomycin and
grown for two days at 37◦C, 90% humidity and 5% CO2, then medium being
changed to DMEMwithout phenol red containing 1% Pen-strep on the second
day.
C.7.2 Hep89 cells
Hep89 cells were plated in 10cm3 plates at a density of 2×106 cells per plate in
DMEM containing 10% fetal calf serum, 0.1mM non-essential amino acids,
1.0mM sodium pyruvate and grown for two days at 37◦C, 90% humidity
and 5% CO2, then medium being changed to DMEM without phenol red
containing 10% fetal calf serum, on the second day.
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C.7.3 Addition of test compounds
On the day of the experiment the medium was changed to DMEM without
phenol red and a total of 9µl of 10−5M E2 and 1µl of 3H-17-β-estradiol was
added to 8ml of medium, which was then added to the cells. The cells were
then incubated for a total of 10 hours at 37◦C, 90% humidity and 5% CO2
with samples of 1ml being taken each hour.
C.7.4 Separation of of steroids from medium
A total of 1ml of the cellular medium was added to 5ml of CH2Cl2, which
was placed at 4◦C the night before, after which 1µl of a 10 times dilution of
3H-dexamethasone was added and the samples vortexed for 2 minutes. After
vortexing the supernatant was removed and added to a 5ml glass tube and
the samples dried under nitrogen flow.
C.7.5 Separation of steroids by thin layer chromatog-
raphy
Thin layer chromatography (TLC) plates were supplied by Merck (Cat. no.
1.05554). Steroid preparation of 3H-17-β-estradiol and 3H-dexamethasone
(1µl of each labelled steroid was added to the samples) prepared in 100µl
absolute EtOH as well as the samples were spotted onto various lanes, sepa-
rated by 1cm, on the TLC plates.
The TLC plate was then placed in a chamber which contained 70% chlo-
roform and 30% Acetone, pre-equilibrated for 1 hour, and run for one and
a half hours. After this the plates were removed and allowed to dry in the
air. The steroids were then cut from the plate in 1cm sections and placed
in 3ml scintillation fluid after which they were left overnight in a cupboard.
The samples were then counted with a Beckman scintillation counter for 10
minutes on a program used to detect tritium.
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The results were analysed by correcting for counting efficiency, this was done
by comparing the amount of 3H-dexamethasone in the sample to the amount
initially added. The ratio of final over initial amount of 3H-dexamethasone
was used to correct the samples for extraction efficiency of the steroids from
the medium.
C.8 Determination of amount of SHBG in
Hep89 cells
Hep89 cells were plated in 10cm3 plates at a density of 2×106 cells per plate
in DMEM containing 10% fetal calf serum, 0.1mM non-essential amino acids,
1.0mM sodium pyruvate and grown for two days at 37◦C, 90% humidity and
5% CO2, then medium being changed to DMEM without phenol red con-
taining 10% fetal calf serum, on the second day.
On the third day the medium was removed and the samples were exposed
to DMEM ± E2 (10−5M) for a period of 24 hours. The medium was then
removed and stored at -20◦C after which the cells were lysed by adding 1ml
lysis solution and freezing overnight. The lysate (intracellular SHBG) and
the medium (extracellular SHBG) was then sent off for testing at the Univer-
sity of Cape Towns chemical pathology unit, located in Groote Schuur. The
samples were analysed using a SHBG immunoradiometric assay (IRMSA)
supplied by Orion diagnostics (Cat. No. 68563) for the presence of SHBG.
C.9 Determination of cell volumes
COS-1 cells were seeded at 2×106 cells per well in 10cm3 plates and grown
for 4 days in DMEM containing 10% fetal calf serum and 1% Penicillin-
Streptomycin as described in Appendix C.2.1. The cells were then removed
from the plate as described in Appendix C.2.1 and the extracellular volume
determined. The intracellular volume was determined by drawing up a small
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sample, of the lysed cells, into a capillary tube. The samples were then spun
for 5 minutes in a haematocrit centrifuge and the ratio of cells to medium
determined.
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Materials
D.1 Plasmids
The ERE.tk-Luc reporter promoter construct was a kind gift from Dr
D.C. Harnish (Womens Health Research Institute, Wyeth-Ayerst Research,
Radnor, PA USA). It contains two copies of the vitellogenin ERE element up-
stream of a tk promoter and is cloned into the pGL2-basic vector (Promega).
The ERE-vitellogenin reporter promoter construct plasmid contains one
copy of the vitellogenin gene in the pGL2-TATA-lnr plasmid, and was a kind
gift from Dr. K. Korach (Receptor Biology Section, National Institute of
Environmental Health Sciences, Durham, North Carolina)
The pcDNA3-ER-α was a kind gift from Dr. D.C. Harnish. It contains
the cDNA of the human ER-α, which is constitutively expressed, sub-cloned
into the pcDNA3 vector (Invitrogen, San Diego, CA)
The pSV-β-galactosidase was bought from Promega (Cat. no. E1081).
It is used as a positive control for transfection and constitutively expresses
the β-galactosidase gene.
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The pCMV-β-galactosidase reporter gene was obtained from Professor
J. Hapgood. The plasmid is a mammalian reporter vector which expresses
the β-galactosidase gene.
The pGL2-Basic vector was purchased from Promega (Cat. no. E1641).
The vector lacks any eukaryotic promoter and enhancer sequences and con-
tains a luc gene, expression of which is dependent on the insertion of a
promoter in the correct orientation
D.2 Chemicals
Table D.1: Chemicals and reagents
Chemical Supplier Product Number
Acetone Univer 1022040
Bacteriological Agar Merck Bx1
Agarose Seakem 50002
Bovine Serum Albumin Fraction IV Roche 70098729
CaCl.2H20 NT Laboratories R0570
Chloroquine Sigma C6628
Chloroform BDH BB100776B
DCC Fluka 05120
DEAE-Dextran Sigma D-9885
Dichloro Methane Saarchem 1862510 CC
EDTA Saarchem 2236020
17-β-estradiol Sigma E2758
EtOH (Absolute) Merck AB000983.2.5
Glycerol BDH BB101186M
Guanidine HCL Fluka 50950
Hepes Gibco RL 15630-056
KH2PO4 BDH 29608
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Table D.1: (continued)
Chemical Supplier Product Number
KCl Saarchem 5042020
K2HPO4 Merck 3629531
Methanol Univar 4164080 LC
NaCl Merck 5822320
NaOH Saarchem 5822300
NaH2PO4.2H2O Riedel de Han 04269
Na2HPO4.12H2O BDH 30156
Non-essential amino acids Gibco RL 11140-035
Propanol Saarchem 5075040 LC
SDS Saarchem 5283600
Trypsene/Versene Highveld Biological CN 2497
Triton-X100 BDH BB306324M
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